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ABSTRACT	  OF	  DISSERTATION 
	  
	  
THE	  CARDIAC	  L-­‐TYPE	  CALCIUM	  CHANNEL	  DISTAL	  CARBOXYL-­‐	  TERMINUS	  AUTO-­‐
INHIBITION	  IS	  REGULATED	  BY	  CALCIUM	  
The	  L-­‐type	  calcium	  channel	  (LTCC)	  provides	  trigger	  Ca2+	  for	  sarcoplasmic	  reticulum	  
Ca2+-­‐release	   and	  LTCC	   function	   is	   influenced	  by	   interacting	  proteins	   including	   the	  
LTCC	  Distal	  Carboxyl-­‐terminus	  (DCT)	  and	  calmodulin.	  DCT	  is	  proteolytically	  cleaved,	  
and	  re-­‐associates	  with	  the	  LTCC	  complex	  to	  regulate	  calcium	  channel	  function.	  DCT	  
reduces	   LTCC	   barium	   current	   (IBa,L)	   in	   reconstituted	   channel	   complexes,	   yet	   the	  
contribution	  of	  DCT	  to	  ICa,L	  in	  cardiomyocyte	  systems	  is	  unexplored.	  This	  study	  tests	  
the	  hypothesis	  that	  DCT	  attenuates	  cardiomyocyte	  ICa,L.	  We	  measured	  LTCC	  current	  
and	   Ca2+	   transients	   with	   DCT	   co-­‐expressed	   in	   murine	   cardiomyocytes.	   We	   also	  
heterologously	   co-­‐expressed	   DCT	   and	   CaV1.2	   constructs	   with	   truncations	  
corresponding	   to	   the	   predicted	   proteolytic	   cleavage	   site,	   CaV1.2Δ1801,	   and	   a	  
shorter	   deletion	   corresponding	   to	   well-­‐studied	   construct,	   CaV1.2Δ1733.	   DCT	  
inhibited	  IBa,L	  in	  cardiomyocytes,	  and	  in	  HEK	  293	  cells	  expressing	  CaV1.2Δ1801	  and	  
CaV1.2Δ1733.	  Ca2+-­‐CaM	  relieved	  DCT	  block	   in	   cardiomyocytes	  and	  HEK	  cells.	  The	  
selective	  block	  of	  IBa,L	  combined	  with	  Ca2+-­‐CaM	  effects	  suggested	  that	  DCT-­‐mediated	  
blockade	  may	  be	  relieved	  under	  conditions	  of	  elevated	  Ca2+.	  We	  therefore	  tested	  the	  
hypothesis	   that	   DCT	   block	   is	   dynamic,	   increasing	   under	   relatively	   low	   Ca2+,	   and	  
show	  that	  DCT	  reduced	  diastolic	  Ca2+	  at	  low	  stimulation	  frequencies	  but	  spared	  high	  
frequency	   Ca2+-­‐entry.	   DCT	   reduction	   of	   diastolic	   Ca2+	   and	   relief	   of	   block	   at	   high	  
pacing	   frequencies,	   and	   under	   conditions	   of	   supraphysiological	   bath	   Ca2+	  suggests	  
that	   a	   physiological	   function	   of	   DCT	   is	   to	   increase	   the	   dynamic	   range	   of	   Ca2+	  
transients	   in	  response	  to	  elevated	  pacing	   frequencies.	  Our	  data	  motivates	   the	  new	  
hypothesis	  that	  DCT	  is	  a	  native	  reverse	  use-­‐dependent	  inhibitor	  of	  LTCC	  current.	  
KEYWORDS:	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  Carboxyl-­‐Terminus,	  Calcium	  Channel	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Chapter 1: Background 
1.1 Introduction 
Sydney	   Ringer	   published	   a	   series	   of	   papers	   from	   1882	   to	   1883	   that	  
established	  the	  role	  of	  Ca2+	  in	  contraction	  of	  the	  heart[3,	  4].	  	  Calcium	  through	  the	  L-­‐
type	  Ca2+	   channel	   triggers	   contraction	   in	   cardiomyocytes[5,	  6].	   	  Auto-­‐inhibition	  of	  
the	   L-­‐type	   calcium	   channel	   can	   be	   controlled	   by	   its	   proteolytically	   cleaved	   distal	  
carboxyl-­‐terminus[1].	   	  The	   focus	  of	   this	   thesis	   centers	  around	  cardiomyocyte	  Ca2+	  
homeostasis	   underlying	   the	   functional	   role	   of	   the	   L-­‐type	   calcium	   channel	   distal	  
carboxyl-­‐terminus	   (DCT).	   	   The	   introduction	   outlines	   the	  molecular	   and	   functional	  
characteristics	  of	   the	  L-­‐type	  calcium	  channel	   (LTCC)	  expressed	   in	  cardiomyocytes.	  	  
First,	   I	   will	   introduce	   the	   channel,	   associated	   subunits,	   functional	   assays,	  
distribution,	   and	   physiological/pathophysiological	   functions	   in	   cardiomyocytes.	  	  
Then,	  I	  will	  detail	  each	  description	  in	  its	  own	  sub-­‐section.	  	  	  Finally,	  I	  will	  outline	  the	  
thesis	  research	  project	  aims	  at	  the	  end	  of	  the	  chapter.	  
1.2 The L-type Calcium channel 
The	   L-­‐type	   calcium	   channel	   was	   first	   purified	   from	   skeletal	   muscle	  
transverse	   tubules	   by	   Curtis	   and	   Catterall	   in	   1984[7].	   	   L-­‐type	   calcium	   channels	  
provide	  the	  main	  pathway	  for	  Ca2+	  entry	  into	  cardiomyocytes	  (Figure	  1.1)	  [8].	  	  The	  
CACNA1C	   gene	   encodes	   the	   protein	   CaV1.2,	   the	   LTCC	   in	   cardiomyocytes[2].	   The	  
CaV1.2	  L-­‐type	  channel	  coding	  region	  was	  first	  isolated	  in	  rabbit	  heart[2].	  	  CaV1.2	  is	  a	  
voltage-­‐gated	  calcium	  channel	  made	  up	  of	  a	  pore	  forming	  CaV1.2	  α-­‐1-­‐subunit	  that	  is	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part	  of	  a	  multi-­‐protein	  complex.	  	  This	  complex	  is	  made	  up	  of	  the	  CaV1.2	  α-­‐1-­‐subunit	  
and	  accessory	  subunits	  α2δ	  and	  CaVβ	  and	  sometimes	  γ[2,	  5,	  9,	  10].	  	  	  	  There	  are	  four	  
CaVβ	  subunit	  genes	  that	  have	  been	  detected	  in	  the	  heart	  with	  CaVβ2	  and	  CaVβ3	  as	  the	  
predominate	  isoforms	  that	  interact	  with	  CaV1.2	  [11].	   	  The	  CaVβ	  subunit	  can	  modify	  
L-­‐type	   calcium	   channel	   currents	   in	   an	   isoform	   and	   splice	   variant	   specific	  manner	  
[12].	   	   The	   cardiac	   isoform	   and	   splice	   variant	   CaVβ2a	   increases	   L-­‐type	   current	  
densities	  in	  HEK	  over-­‐expression	  systems	  and	  slows	  the	  inactivation	  kinetics	  of	  the	  
channel[13,	   14]	   [15].	   	   CaVβ2a	  hyperpolarizes	   the	   voltage-­‐dependence	  of	   activation	  
resulting	   in	   channel	   openings	   at	   more	   negative	   membrane	   potentials[16].	   	   The	  
primary	   interaction	   site	   for	   the	   CaVβ2	   subunit	   is	   the	   conserved	   α1-­‐interaction	  
domain	   (AID)	   on	   the	   CaV1.2	   I-­‐II	   linker[11,	   16].	   	   CaVβ2a	   functional	   effects	   on	   the	  
Cav1.2	   channel	   include	   increased	   peak	   amplitude,	   faster	   rate	   of	   activation,	  
modification	  in	  rate	  of	  inactivation,	  hyperpolarizing	  shift	  in	  inactivation[17].	  	  CaVβ2a	  
increases	   current	   amplitude	   by	   either	   by	   increased	   open	   probability	   and/or	  
increasing	   the	   number	   of	   channels	   at	   the	   plasma	   membrane	   by	   masking	   an	  
unidentified	  endoplasmic	  retention	  signal	  on	  the	  CaV1.2	  α-­‐1-­‐subunit	  cytoplasmic	  I-­‐II	  
linker[16-­‐18].	  	  	  The	  accessory	  subunits	  α2δ	  is	  transcribed	  from	  a	  single	  gene[11,	  19].	  
Then	  α2δ	  is	  post-­‐transnationally	  cleaved	  into	  α2	  and	  δ.[11,	  19].	  	  The	  subunits	  α2-­‐δ	  
remains	  associated	  by	  a	  disulfide	  linkage.	  	  α2δ-­‐1	  cloned	  from	  skeletal	  muscle	  is	  one	  
of	  the	  four	  known	  isoforms	  including	  α2δ-­‐2	  &	  α2δ-­‐3	  cloned	  from	  brain,	  and	  α2δ-­‐4	  
from	  non	  neuronal	   cells[19].	   	   α2δ-­‐1	   subunit	   isoform	  has	  been	  detected	   in	   cardiac	  
muscle[19].	   	   This	   subunit	   binds	   to	   extracellular	   Domain	   III	   regions	   of	   the	   CaV1.2	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subunit[19].	   	  The	  main	  effect	  of	   the	  combined	  α2-­‐δ	   in	  HEK	  cells	   increases	  current	  
amplitude	  and	  can	  modify	  gating	  kinetics[11,	  19].	  	  Yet,	  the	  role	  in	  the	  heart	  has	  not	  
been	  closely	  studied[11].	   	  Early	  experimental	  designs	  used	  minimal	  components	  in	  
HEK	   cells	   co-­‐expressing	   CaV1.2	   and	   CaVβ2a	   and	   omitting	   α2δ	   to	   determine	   the	  
functional	  role	  of	  CaV1.2	  	  carboxyl-­‐terminus[20].	  	  However,	  co-­‐expression	  of	  α2δ	  has	  
a	  practical	  advantage	  and	  a	  real	  disadvantage.	  	  First,	  co-­‐expression	  of	  α2δ	  increases	  
IBa,L	   current	   2-­‐fold	   in	   my	   hands	   (data	   not	   shown).	   	   Yet,	   when	   considering	   co-­‐
expressing	   multiple	   cDNAs	   into	   a	   HEK	   system,	   I	   elected,	   like	   others,	   to	   use	   the	  
minimally	   required	   subunit	   expression	   of	   channel,	   beta	   subunit,	   and	   proteins	  
tested[20].	  	  
The	  L-­‐type	  calcium	  channel	  is	  part	  of	  a	  superfamily.	  	  Voltage	  gated	  channels	  
are	   classified	   by	   voltage	   dependence	   of	   activation.	   	   High	   voltage	   activated	   (HVA)	  
gated	  channels	  are	  called	  L-­‐,	  P/Q-­‐,	  and	  N-­‐type[8].	   	  L-­‐	  signifies	  long	  lasting	  currents	  
when	  Ba2+	  is	  the	  charge	  carrier,	  N-­‐	  for	  Neural,	  P-­‐	  for	  cerebellar	  Purkinje	  cells,	  Q-­‐	  &	  
R-­‐	   cerebellar	   granule	   cells[2].	   Low	   voltage	   activated	   (LVA)	   channels	   are	   called	   T-­‐
type	  for	  transient	  current	  (Figure	  1.1)	  [21,	  22].	  	  Distribution	  of	  L-­‐	  and	  T-­‐type	  voltage	  
gated	   Ca2+	   channels	   are	   both	   tissue	   specific	   and	   development	   dependent.	   	   For	  
example,	   in	  mouse	   fetal	  ventricular	  myocytes	  (FVM),	   there	  are	  two	  L-­‐type	  calcium	  
channels	  and	  one	  T-­‐type	  channel	  expressed,	  CaV1.2,	  CaV1.3	  and	  Cav3.1	  respectively.	  	  
CaV3.1	  represents	  the	  T-­‐type	  calcium	  channel	  expressed	  during	  early	  development	  
in	  fetal	  ventricular	  myocytes.	  	  CaV1.3	  and	  CaV3.1	  are	  the	  dominant	  calcium	  channels	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expressed	  up	  to	  embryonic	  day	  16,	   then	  CaV1.2	  expression	  becomes	  dominant[23-­‐
25].	  	  
1.3 CaV1.2 is a voltage gated calcium channel 
The	  earliest	  cardiac	  calcium	  channel	  currents	  were	  recorded	  in	  purkinje	  fibres	  
from	   sheep	   and	   calf	   hearts[26].	   	   Functional	   assays	   for	   L-­‐type	   calcium	   channels	  
include	   whole-­‐cell	   and	   single	   channel	   patch-­‐clamp,	   calcium	   imaging,	   cardiac	   or	  
smooth	  muscle	  contraction,	  and	  hormone	  secretion[2,	  27].	  	  Ca2+	  through	  the	  L-­‐type	  
calcium	  channel	  is	  called	  Ca2+ current	  (ICa,L)[2,	  28].	   	  CaV1.2	  ion	  selectivity	  increases	  
from	   Ca2+	   >Sr2+	   >Ba2+	   >>Mg2+.	   	   Experimentally,	   Ba2+	   (25pS)	   is	   routinely	   used	   for	  
recording	   currents	   (IBa,L)	   given	   its	   greater	   conductivity	   than	   Ca2+	   (9pS)[29].	  	  
However,	  CaV1.2	  is	  more	  selective	  for	  Ca2+.	  	  Ca2+	  coordinating	  with	  acidic	  side	  chains	  
projecting	   into	   the	   pore	   achieves	   selectivity.	   Thus	   ions,	   Ca2+	   ions	   bind	   tightly	   and	  
will	  have	  the	  lowest	  conductance[29].	  	  	  
The	  CaV1.2	  subunit	   is	  a	  190-­‐250	  kDa	  protein	  made	  of	  4	  repeats	  (DI-­‐DIV)	  of	  
six	  transmembrane	  regions	  (S1-­‐S6)	  each	  with	  a	  pore	  loop	  (S5-­‐S6)[5,	  9,	  30,	  31].	  	  The	  
hydrophilic	   pore	   of	   the	   CaV1.2	   subunit	   comprises	   the	   ion	   selectivity	   filter	   (Figure	  
1.2).	  	   	  Depolarization	  of	  the	  membrane	  favors	  transitions	  of	  the	  CaV1.2	  subunit	  from	  
closed	   state	   (C)	   to	   an	   open	   state	   (O)[8].	   	   The	   molecular	   transitions	   are	   termed	  
channel	  gating,	  and	  Markovian	  models	  capture	  channel	  gating.	  	  In	  many	  models,	  the	  
voltage	  dependent	  activation	  gating	  is	  delayed,	  and	  described	  as	  a	  two-­‐closed-­‐state	  
reaction,	  such	  as:	  C	  ßà	  CßàO.	  The	  transition	  rate	  constants	  (k)	  are	  functions	  of	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voltage	  whereby	  depolarization	  speeds	  activation	  (right	  to	  left	  transition,	  CàCàO);	  
conversely	  repolarization	  speeds	  closing	  (OàC)[8].	  	  Channel	  gating,	  is	  controlled	  by	  
the	  CaV1.2	  voltage	  sensor	  in	  the	  S4	  transmembrane	  segment	  of	  each	  repeat.	  	  The	  α-­‐
helical	   transmembrane	  S4	  segment	  contains	  positive	  charges	   in	  register	  (Arg,	  Lys)	  
that	  sense	  transmembrane	  potential.	   	  Depolarization	  moves	  S4	  up,	   that	   is	   towards	  
the	   extracellular	   space	   upon	   depolarization	   [25].	   	   By	   definition,	   the	  movement	   of	  
charge	   through	   an	   electric	   field	   generates	   current.	   	   Such	   current	   is	   termed	   gating	  
current,	  in	  contrast	  to	  the	  ionic	  current	  generated	  by	  movement	  of	  ions	  through	  the	  
pore	   of	   the	   channel.	   Macroscopic	   current	   (I)	   is	   equal	   to	   the	   product	   of	   unitary	  
channel	  current	  (i)	  by	  the	  number	  of	  channels	  (N)	  and	  by	  the	  open	  probability	  of	  the	  
channel	  (Po).	   	   	  Single	  channel	  recordings	  allow	  direct	  assessment	  of	  Po	  and	   i.	   	  The	  
single	   channel	   currents	   with	   short	   open	   (O)	   times	   are	   called	   mode	   1[8].	   	   Single	  
channel	   currents	   with	   long	   open	   times	   (O)	   are	   called	   mode	   2.	   	   Single	   channel	  
current	   mode	   0	   means	   no	   opening	   at	   all[8].	   	   Although	   gating	   current	   occurs	   on	  
average	  prior	   to	   ionic	   current,	   the	   stochastic	  nature	  of	   channel	   opening	   results	   in	  
some	   overlap	   of	   gating	   and	   ionic	   current.	   	   Therefore,	   measurements	   of	   gating	  
current	  over	  the	  entire	  voltage	  range	  require	  complete	  blockade	  of	  transmembrane	  
ionic	  conductance.	   	  Alternatively,	  macroscopic	  current	  waveforms	  measured	  at	  the	  
reversal	   potential	   isolates	   the	   gating	   charge,	   the	   movement	   of	   the	   charged	   S4	  
segment[8].	   	   Gating	   charge	   is	   a	  metric	   for	   the	   number	   of	   channels	   with	  movable	  
voltage	  sensors	  in	  the	  membrane[32].	  	  	  Moreover,	  the	  ratio	  of	  gating	  charge	  to	  ionic	  
current	  is	  a	  readout	  for	  coupling	  between	  voltage-­‐sensing	  and	  channel	  opening.	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L-­‐type	   calcium	   current	   in	   cardiac	   myocytes	   is	   a	   major	   determinant	   of	  
calcium-­‐induced	   Ca2+	   release	   (CICR)	   (Figure	   1.3)	   [5]	   .	   	   The	   Ryanodine	   receptor	  
(RyR2)	  on	  the	  SR	  is	  gated	  by	  Ca2+	  from	  the	  LTCC[33].	  	  More	  LTCC	  Ca2+entry	  leads	  to	  
more	   SR	   Ca2+	   release	   [34,	   35].	   	   Upon	   depolarization,	   LTCCs	   increase	   the	   Ca2+	  
concentration	   in	   the	  dyadic	   cleft	   between	   the	  LTCC	  and	   the	  RyR2.	   	  As	  dyadic	   cleft	  
Ca2+	  concentration	  increases,	  Ca2+	  binds	  to	  RyR2,	  in	  turn	  causes	  RyR2	  to	  open	  for	  SR	  
Ca2+	  release[33].	  	  Normally,	  negative	  potentials	  limit	  openings	  of	  the	  LTCC	  that	  could	  
trigger	  Ca2+	   gated	  RyR2	  openings.	   	  RyR2	  mediated	   release	  of	   SR	  Ca2+	   in	   a	   spatially	  
and	  temporally	  restricted	  mode	  is	  called	  a	  Ca2+	  spark.	   	  An	  ensemble	  of	  Ca2+	  sparks	  
increase	   Ca2+	   concentration	   in	   the	   dyadic	   cleft	   that	   can	   trigger	   a	   global	   SR	   Ca2+	  
release.	   	   Next,	   I	   will	   break	   down	   the	   determinants	   of	   LTCC	   channel	   currents	   to	  
expand	  the	  relationship	  between	  voltage	  control	  and	  channel	  opening.	  	  	  
As	  mentioned	  above,	  ICa,L	  is	  the	  product	  of	  single	  channel	  currents	  (iCa,L),	  
channel	  number	  (N),	  and	  open	  probability	  (Po);[36,	  37]	  
???,? = ???,?  ×  ?  ×  ??	  
Po	  is	  dependent	  on	  membrane	  voltage	  (Vm)[37].	  	  N	  can	  be	  regulated	  but	  assumed	  to	  
be	   unchanged	   on	   short	   time	   scale.	   	   The	   gating	   and	   voltage	   sensing	   of	   the	   LTCC	  
define	  Po.	   	  Finally,	  unitary	   iCa,L	  	   (noted	  by	   lower	  case	   i)	   is	  assumed	   	  unchanged	   for	  
any	  given	  potential.	  For	  an	  open	  channel	  the	  magnitude	  of	  ICa,L	  is	  determined	  by	  the	  
Ca2+	   electrochemical	   gradient[37].	   	   LTCC	  Po	   is	   comparatively	   low	  during	   diastole,	  
thus	   limiting	   CICR	   at	   relatively	   low	   voltages[35,	   38].	   	   Conversely,	   LTCC	   Po	   is	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relatively	   higher	   as	   voltage	   increases.	   	   The	   electrochemical	   gradient	   creates	   a	  
greater	  driving	  force	  for	  Ca2+	  at	  more	  negative	  voltages.	   	  High	  driving	  force	  of	  Ca2+	  
through	  the	  LTCC	  increases	  the	  probability	  of	  RyR2	  openings	  (Figure	  1.4).	  	  Relatively	  
low	   Po	   of	   LTCC	   at	   very	   negative	   voltages	   protects	   the	   cytosol	   from	   potentially	  
pathological	  external	  Ca2+	  entry.	  Conversely,	  driving	  force	  for	  Ca2+	  through	  the	  LTCC	  
is	   low	  at	  high	  voltages,	   thus	   low	  driving	   force	  of	  Ca2+	  decreases	   the	  probability	  of	  
RyR2	  openings[37].	  	  	  SR	  Ca2+	  release	  and	  ICa,L	  	  amplitude	  track	  a	  similar	  bell	  shaped	  
dependence	  on	  membrane	  voltage[37,	  39].	   	  As	  membrane	  voltages	  becomes	  more	  
positive,	   Po	   increases	   and	  more	   Ca2+	   entry	   is	   available	   to	   stimulate	  RyR2	   opening	  
(Figure	  1.4)	  [37].	  	  	  The	  ratio	  of	  LTCCs	  to	  RyR2s	  in	  adult	  myocytes	  is	  ~12	  :	  100[33,	  37,	  
40].	   	   The	   amplification	   of	   the	   ICa,L	   by	   SR	   Ca2+	   release	   (SR	   Ca2+	   release/ICa,L)	   is	  
measured	   by	   Ca2+	   imaging	   transients	   and	   Vm	   of	   ICa,L[37].	   	   Increased	   ICa,L	  
amplification	   is	   observed	   at	   more	   negative	   Vm.	   	   In	   summary,	   Po	   at	   negative	  
potentials	  are	  more	  infrequent,	  but	  for	  a	  given	  opening	  ICa,L	   is	  greater[37].	   	  This	   in	  
turn	  activates	  Ca2+	  gated	  RyR2	  to	  open,	  releasing	  the	  Ca2+	  store	  from	  the	  SR.	  
	   CaV1.2	   inactivation	   limits	   Ca2+	   entry	   across	   the	   cell	   membrane	   during	   prolonged	  
depolarization[41].	  	  Channel	  inactivation	  is	  a	  transition	  from	  opening	  to	  a	  non-­‐conducting	  
state[42].	   	  CaV1.2	   inactivation	  determines	  action	  potential	  duration	  and	  refractory	  period	  
of	  excitable	  cells[42].	  Excessive	  Ca2+	  entry	  can	  contribute	  to	  pathological	  cytosolic	  calcium	  
overload[43].	   	   Therefore,	   Ca2+	   entry	   inactivation	   is	   crucial	   for	   normal	   function,	   and	   is	  
tightly	   controlled	   by	   two	   distinct	   processes,	   voltage	   dependence	   or	   intracellular	   calcium	  
dependence[41,	   44,	   45].	   	   	   CaV1.2	   structure-­‐function	   studies	   suggest	   that	   the	   elements	   of	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voltage	  dependent	  inactivation	  (VDI)	  are	  in	  the	  domain	  I-­‐II	   linker	  and	  the	  S6	  segments	  of	  
the	  four	  transmembrane	  repeats[46].	   	  CaV1.2	  VDI	   is	  experimentally	   isolated	  from	  calcium	  
dependence	   inactivation	  (CDI)	  by	  using	  Ba2+	  as	   the	  charge	  carrier	   IBa,L.	  Hence,	  CaV1.2	   IBa,L	  
peak	  current	  decay	  is	  governed	  by	  voltage.	  	  A	  consequence	  of	  VDI	  loss	  of	  function	  is	  seen	  in	  
the	  cardiac	  CaV1.2	  mutation,	  G406R	  that	  is	  located	  on	  S6	  of	  domain	  I.	  	  This	  mutation	  found	  
in	  Timothy	  Syndrome	   leads	  to	  prolongation	  of	  QT	   intervals	  causing	  multiple	  arrhythmias	  
and	   sudden	   death[43].	   	   In	   my	   dissertation	   work,	   I	   examine	   the	   consequence	   of	   CaV1.2	  
proximal	  carboxyl-­‐terminal	  interacting	  proteins	  on	  inactivation	  using	  both	  VDI	  and	  CDI.	  
CaV1.2	   calcium	   dependent	   inactivation	   (CDI)	   is	   modulated	   by	   Ca2+/calmodulin	  
which	   is	   critical	   for	   ICa,L	   dependent	   feedback[47].	   	   The	   structural	   underpinning	   of	  
CDI	   is	  a	  result	  of	  Ca2+	  binding	  the	  pre-­‐associated	  calmodulin	  protein	  (CaM)	  on	  the	  
CaV1.2	  proximal	   carboxyl-­‐terminus	  at	   the	  CB/IQ	  domain[44,	  48-­‐55].	  Calmodulin	   is	  
constitutively	   associated	   with	   the	   CaV1.2	   proximal	   carboxyl-­‐terminus	   (PCT)[11].	  	  
CaM	  binds	  the	  CaV1.2	  motif	  at	  amino	  acid	  1653-­‐1663	  rabbit	  sequence[56]	  [57].	  	  CaM	  
is	   made	   up	   of	   an	   N-­‐	   and	   C-­‐lobe.	   	   Each	   lobe	   contains	   two	   Ca2+	   binding	   EF	   hand	  
motifs[55].	   	  CaV1.2	   ICa,L	   is	  modulated	  by	  CaM	  when	  Ca2+	  binds	  these	   four	  sites[55].	  
Calcium	   activated	   CaM	   reorients	   its	   attachments	   that	   causes	   a	   conformational	  
change	  of	   the	   carboxyl-­‐terminus	  3D	  structure	  enhancing	   the	  decay	  of	   ICa,L[44,	  58].	  	  
Studies	   have	   shown	   specificity	   of	   CDI	   though	   CaM	   mutagenesis.	   	   At	   the	   level	   of	  
CaV1.2	  current,	  disruption	  of	  CaM	  interaction	  with	  the	  CB/IQ	  domain	  may	  result	  in	  
reduced	   CDI	   effect[58].	   For	   example,	   engineered	   CaM1234	   is	   Ca2+	   insensitive	   by	  
mutation	  of	  the	  EF	  motifs	  on	  the	  N-­‐	  and	  C-­‐	  Lobe[51].	  	  Over-­‐expression	  of	  CaM1234	  in	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rat	   ventricular	   cardiomyocytes	   results	   in	   prolonged	   action	   potential	   durations	  
(APD)[59].	   	   Removing	   the	  Ca2+	   dependent	   feedback	  by	   a	  modified	  CaM	  prolonged	  
the	  action	  potential	  duration	  4-­‐	  5-­‐fold[51].	  Functional	  CaM	   is	   essential	   for	   cardiac	  
cytosolic	   Ca2+	   homeostasis	   as	   a	   negative	   feedback	   control	   of	   Ca2+	   entry	   through	  
CaV1.2[57,	  58].	   	  Another	  example	  of	  CaM	   interaction,	  CaV1.2	  co-­‐express	  with	  small	  
GTPase	  Rem	  in	  HEK	  293	  cells	  results	  in	  relatively	  slow	  CDI[60].	  	  Rem	  interacts	  with	  
a	   CaV1.2	   proximal	   C-­‐terminal	   peptide	   segment	   including	   the	   CB/IQ	   domain	   [60].	  	  
Over-­‐expression	   of	   calmodulin	   (CaM),	   a	   CB/IQ	   interacting	   protein,	   disrupts	   the	  
Rem-­‐CaV1.2	  peptide	  segment	  interaction	  in	  a	  Ca2+	  dependent	  manner	  [60].	  Together,	  
co-­‐expression	  of	  exogenous	  CaM	  using	  CDI	  as	  a	  readout	  of	  CaM	  interaction	  on	  CaV1.2	  
proximal	   carboxyl-­‐terminus,	   can	   be	   used	   to	   evaluate	   the	   functional	   interaction	   of	  
associated	  proteins.	  	  
	  
1.4 L-type Calcium channel modulation by kinases 
The	  large	  intracellular	  CaV1.2	  carboxyl-­‐terminus	  is	  a	  target	  for	  regulation	  by	  Ca2+,	  
CDI,	   facilitation,	   kinase	   regulation,	   and	   transcriptional	   regulation	   of	   the	   CaV1.2	  
channel	  (Figure	  1.5)	  [24,	  25,	  61].	  	  CaV1.2	  is	  the	  substrate	  of	  regulation	  by	  interacting	  
proteins.	  Some	  examples	  of	   interacting	  proteins	  and	  effects	  in	  cardiomyocytes	  are;	  
1.)	  CaM	  activated	  calmodulin/kinase	  II;	   	   ICa,L	   facilitation,	  2.)	  protein	  kinase	  C	  (PKC)	  
Ca2+	   mediated	   	   channel	   phosphorylation,	   3.)	   protein	   kinase	   A,	   activated	   through	  
adenylyl	  cyclase	  by	  β-­‐adrenergic	  agonist,	  4.)	  and	  protein	  kinase	  D	  (PKD)	  activated	  
through	  adenylyl	  cyclase	  	  by	  α-­‐adrenergic	  agonist.	  	  CaM	  mediated	  CaMKII	  activation	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increases	   Ca2+	   dependent	   facilitation	   (CDF)	   of	   L-­‐type	   Calcium	   channels	   and	   is	  
tethered	   to	   the	   Cav1.2	   proximal	   carboxyl	   terminus[62].	   	   Increased	   heart	   rate	  
enhances	  inward	  ICa,L	  in	  a	  positive	  force	  frequency	  relationship[11].	  	  CaMKII	  changes	  
modal	  gating	  of	  the	  L-­‐type	  calcium	  channel	  similar	  to	  β-­‐adrenergic	  enhancement	  of	  
ICa,L[11].	  	  Recent	  reports	  show	  PKD	  regulates	  human	  Cav1.2	  through	  Ser1884	  on	  the	  
Cav1.2	   carboxyl-­‐terminus[63].	   	   Finally,	   enhanced	   L-­‐type	   calcium	   current	   by	   β-­‐
adrenergic	   stimulation	  has	  been	  a	   focus	  of	   study	   for	   several	  decades[11].	   	  Protein	  
kinase	  A	  (PKA)	  is	  activated	  by	  β-­‐adrenergic	  agonists[11].	  	  PKA	  stimulation	  of	  the	  L-­‐
type	   calcium	   channel	   changes	  modal	   gating	   by	   longer	   and	  more	   frequent	   channel	  
openings,	  mode	  2[11].	   	  The	  CaV1.2	  carboxyl-­‐terminus	  (Ser1928	  and	  Ser1700)	  and	  the	  
β2a	  subunit	  (Ser478	  and	  Ser479)	  are	  specific	  targets	  for	  PKA	  phosphorylation[11,	  64].	  	  
However,	   Ser1928	   may	   not	   be	   necessary	   for	   β-­‐adrenergic	   enhancement	   ICa,L	   in	  
cardiomyocytes	   and	   may	   also	   be	   a	   substrate	   for	   PKD	   phosphorylation[63,	   65].	  	  
Cav1.2	   over-­‐expression	   in	  HEK	   cells	   have	   not	   always	   been	   able	   to	   recapture	   PKA	  
phosphorylation.	   	   A	   kinase	   anchoring	   protein	   15	   (AKAP15)	   is	   required	   in	  
heterologous	  systems	  to	  recapitulate	  β-­‐adrenergic	  enhancement	  ICa,L[11,	  65].	  	  	  AKAP	  
is	   associated	   with	   the	   CaV1.2	   distal	   carboxyl-­‐terminus	   at	   a.a.2057-­‐2115	   and	  
mediates	  association	  with	  PKA	  signaling	  of	   the	  channel[66,	  67].	   	  Calcium	  activated	  
Protein	  Kinase	  C	  (PKC)	  has	  been	  demonstrated	  to	  phosphorylate	  CaV1.2	  Ser1928	  in	  




1.5 L-type calcium channel distal carboxyl-terminus 
The	   L-­‐type	   calcium	   channel	   found	   in	   native	   tissues	   often	   have	   a	   truncated	  
CaV1.2	  subunit	  at	  the	  distal	  carboxyl-­‐terminus	  (DCT)[30,	  59,	  69].	  	  Cardiac	  CaV1.2,	  the	  
main	   pore-­‐forming	   subunit,	   is	   an	   ~2171	   amino	   acid	   protein	   with	   a	   predicted	  
molecular	  mass	   of	  ~250kDa	   [70-­‐72].	   	   The	   precise	   length	   varies	  with	   species	   [72]	  
and	  splice	  variants	  [73].	  	  A	  conserved	  feature	  of	  CaV1.2	  is	  that	  the	  carboxyl	  terminus	  
is	   located	   in	   the	   cytosol	   space.	   	   	   The	   CaV1.2	   distal	   carboxyl-­‐terminus	   (DCT)	   is	   a	  
protein	  with	  a	  predicted	  mass	  of	  ~37	  kDa	  [1,	  74].	  Spectroscopy	  studies	  show	  that	  
the	  closely	  related	  CaV1.1	  isoform	  is	  truncated	  at	  ~	  amino	  acid	  1800	  in	  the	  carboxyl-­‐
terminus[1,	   74].	   CaV1.2	   heterologously	   expressed	   in	   non-­‐excitable	   cells	   are	   not	  
processed	  as	  in	  cardiomyocytes,	  rather	  it	  functions	  as	  a	  full-­‐length	  ~250kDa	  protein.	  	  
Western	   blot	   studies	   of	   CaV1.2	   in	   cardiomyocytes	   consistently	   show	   CaV1.2	  
migrating	  as	  a	  190	  and	  a	  240kDa	  protein.	  DCT	   is	  also	   found	   to	  be	   localized	   to	   the	  
nucleus	  where	  it	  can	  modify	  gene	  expression	  in	  neurons	  [75]	  or	  cardiomyocytes[24].	  	  	  
The	  Cav1.2	  carboxyl-­‐terminus	  domains	  continue	  to	  be	  defined	  since	  it	  was	  initially	  
reported	  to	  auto-­‐regulate	  L-­‐Type	  currents	  [76].	  
1.6 Regulation of CaV1.2 by DCT 
In	   1994	   Wei	   et.	   al.	   reported	   that	   modifications	   to	   the	   CaV1.2	   carboxyl-­‐
terminus	  resulted	  in	  a	  change	  in	  channel	  Po[76].	  	  They	  assessed	  the	  functional	  role	  
for	   the	  665	  amino	  acid	  carboxyl-­‐terminus	  by	  constructing	  deletion	  mutants	  of	   the	  
rabbit	  cardiac	  CaV1.2[76].	  	  As	  a	  result	  of	  deleting	  ~70%	  (CaV1.2Δ1733)	  of	  the	  distal	  
carboxyl-­‐terminus,	   inward	   IBa,L	   increased	   4-­‐6	   fold[76].	   	   IBa,L	   increased	   without	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change	  to	  charge	  movement	  during	  voltage	  dependent	  gating	  suggesting	  no	  change	  
in	   CaV1.2	   channel	   expression[76].	   	   In	   addition,	   single	   channel	   recordings	   did	   not	  
reveal	  any	  change	  in	  unitary	  conductance[76].	  	  As	  defined	  in	  an	  earlier	  section,	  the	  
whole	   cell	   current	  density	   (I)	   is	   described	   as	   I=i	  x	  N	  x	  Po,	  with	   i	   as	   single	   channel	  
conductance,	  N	  as	  the	  number	  of	  channels,	  and	  Po	  as	  the	  open	  probablility25,26,[76].	  
The	  combination	  of	  unaltered	  (i)	  and	  (N)	   suggests	   that	  70%	  deletion	  of	   the	  CaV1.2	  
carboxyl-­‐terminus	   increased	   current	   (I)	   density	   leading	   to	   increased	  Po[76].	   	   It	   is	  
noted	   in	   this	   paper	   that	   additional	   deletion	   of	   the	   carboxyl-­‐terminus	   including	  
CaV1.2Δ1623	   results	   in	   loss	   of	   channel	   expression[76].	   	   The	   next	   refinement	   in	  
CaV1.2	  carboxyl-­‐terminus	  functional	  role	  is	  examining	  the	  665	  amino	  acid	  segment	  
membrane	  targeting	  and	  L-­‐type	  current	  inhibitory	  domain.	  
Gerhardstein	   et.al.	   generated	   a	   set	   of	   rabbit	   CaV1.2	   carboxyl-­‐terminus	  
deletion	  mutants	   to	   identify	   a	   proline	   rich	   domain	   amino	   acid	   region	   1623-­‐1666	  
that	   mediates	   membrane	   targeting[77].	   	   Dubuis	   delivered	   a	   short	   rat	   Cav1.2	  
carboxyl-­‐terminal	  peptide	  with	  residues	  1973-­‐2001	  by	  whole	  cell	  patch	  pipette	  and	  
recorded	   a	   decrease	   in	   L-­‐type	   calcium	   channel	   current	   density	   in	   adult	   rat	  
cardiomyocytes[78].	  	  Furthermore,	  Gao	  applied	  CaV1.2	  carboxyl-­‐terminus	  fragments	  
to	   the	  pipette	  solution	  to	  recapitulate	   the	   inhibition	  of	   IBa,L	  whole	  cell	  patch	  clamp	  
currents	   in	   HEKs	   expressing	   CaV1.2Δ1905	   and	   CaV1.2Δ2024	   truncated	   channels	  
compared	   to	   CaV1.2Δ1733,	   1905,	  &	   2024	   alone[30].	   	   As	   a	   result	   of	   these	   findings	  
plus	  the	  findings	  above,	  a	  map	  of	  the	  CaV1.2	  carboxyl-­‐terminus	  functional	  role	  was	  
beginning	  to	  emerge[20,	  30,	  77,	  79].	  	  The	  CaV1.2	  distal	  carboxyl-­‐terminus	  included	  a	  
	  	  
13	  
region	   from	  amino	  acids	  1733-­‐2171	  with	  1733-­‐~1900	  as	   the	  DCT	  binding	   region,	  
1974-­‐2000	   as	   the	   proline	   rich	   domain,	   and	   finally	   as	   Gao’s	   paper	   revealed	   2024-­‐
2171	   to	   be	   the	   inhibitory	   domain[30].	   	   Hulme	   provided	   the	   first	   functional	  
characterization	   of	   the	   CaV1.2	   auto-­‐inhibitory	   distal	   carboxyl-­‐terminus[1].	   Co-­‐
expression	  of	  truncated	  CaV1.2Δ1821	  with	  distal	  carboxyl-­‐terminus	  1822-­‐2171	  is	  a	  
re-­‐associated	   as	   a	   molecular	   complex[1].	   	   DCT	   1822-­‐2171	   likewise,	   inhibited	  
CaV1.2Δ1821	  IBa,L	   in	  HEK	  293	  heterologous	  over-­‐expression	  systems[1].	  Formation	  
of	   the	   auto-­‐inhibitory	   complex	   reduced	   coupling	   efficiency	   of	   voltage	   sensing:	  
channel	   opening,	   shifting	   voltage	   dependence	   of	   activation	   towards	   positive	  
membrane	  potentials[1].	  	  	  
1.7 L-type Calcium channel cardiomyocyte cytosolic Ca2+ homeostasis 
	   CaV1.2	  channels	  are	  found	  in	  cardiac	  muscle,	  smooth	  muscle,	  endocrine	  cells,	  
and	   neurons.[2]	   The	   physiological	   function	   for	   CaV1.2	   includes	   excitation-­‐
contraction	   coupling	   in	   cardiac	   or	   smooth	  muscle,	   action	  potential	   propagation	   in	  
sinoatrial	  and	  atrioventricular	  node,	  synaptic	  plasticity,	  and	  hormone	  secretion[2].	  	  	  
CaV1.2	   is	   the	   main	   entry	   for	   external	   Ca2+	   into	   the	   cardiomyocyte	   and	   its	  
regulation	   contributes	  directly	   to	   cytosolic	  Ca2+	  homeostasis	   [5,	   6,	   21,	   25,	   31,	   37].	  	  
Disruption	   of	   CaV1.2	   expression	   or	   function	   can	   contribute	   to	   pathophysiological	  
cytosolic	   Ca2+.	   	   For	   example,	   altered	   expression	   of	   CaV1.2	   is	   detrimental	   to	   heart	  
function	  and	  development.	   	  CaV1.2-­‐/-­‐	   knockout	   is	   embryonic	   lethal	  past	  embryonic	  
day	   14	   in	   fetal	   ventricular	   mice	   [80,	   81].	   	   Alternatively,	   increased	   expression	   of	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CaV1.2	   also	   greatly	   alters	   cardiomyocyte	   function.	   	   L-­‐type	   calcium	   channel	   over-­‐
expression	   transgenic	   mouse	   model	   resulted	   in	   an	   increase	   in	   calcium	   into	   the	  
cardiomyocyte	   resulting	   in	   an	   increased	   contractile	   force,	  without	  modification	   in	  
expression	  of	  accessory	  subunits.	  	  The	  major	  findings	  of	  this	  murine	  model	  were;	  1.)	  
weakened	   response	  of	   beta-­‐adrenergic	   signaling	  pathway,	   and	  2.)	   development	   of	  
cardiac	  hypertrophy	  and	  severe	  cardiomyopathy	  slowly	  over	  time	  with	  age.[82-­‐84].	  	  
Muth	  et.al.	  in	  1999	  postulates	  that	  PKC	  is	  increased	  by	  the	  increase	  calcium	  through	  
the	  cardiac	  channel	  preceding	  cardiac	  hypertrophy,	  suggesting	  an	  endpoint	  example	  
of	   altered	   transcription	  of	   the	  L-­‐type	   calcium	  channel	   [82].	   	  Enhanced	  CaV1.2	  Ca2+	  
through	   the	   channel	   can	   be	   mediated	   by	   kinases	   indirectly	   by	   increasing	   CaV1.2	  
channel	   number	   subunit	   [85,	   86].	   	   Stimulation	   of	   PKA	   has	   also	   been	   shown	   to	  
change	  transcriptional	  regulation	  of	  L-­‐type	  calcium	  channels	  with	  a	  404%	  increase	  
in	   transcription	   rate	   initiation	   for	   the	   CaV1	   subunit	   [85,	   86].	   	   Finally,	   CaV1.2	   Ca2+	  
currents	  can	  be	  increased	  by	  mutations	  in	  the	  channel.	   	  Timothy	  syndrome	  is	  a	  de	  
novo	   mutation	   in	   the	   CaV1.2	   G406R	   that	   causes	   incomplete	   channel	   voltage	  
inactivation[43,	  87,	  88].	  	  In	  summary,	  CaV1.2	  expression	  and	  function	  is	  essential	  for	  
cardiomyocyte	  cytosolic	  Ca2+	  homeostasis.	  
1.8 Summary 
Ca2+	   is	  essential	   for	  cardiac	  contraction	  [4,	  26].	   	  The	  cardiac	  L-­‐type	  calcium	  
channel	   coding	   region	   was	   first	   isolated	   in	   rabbit	   for	   CaV1.2	   [2].	   	   Cardiomyocyte	  
CaV1.2	  is	  part	  of	  a	  heteromultimeric	  complex	  composed	  of	  a	  pore	  forming	  CaV1.2	  α-­‐
1-­‐subunit,	   CaVβ2	   subunit,	   α2δ,	   and	   sometimes	   ϒ	   [22,	   69,	   79,	   89,	   90].	   	   CaV1.2	   α-­‐1-­‐
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subunit	   comprises	   four	   homologous	   repeats	   containing	   six	   transmembrane	  
segments	   (Figure	  1.2)	   [89].	   	   CaV1.2	   is	   a	   high	   voltage	   gated	   channel	  with	   a	   voltage	  
sensor	   on	   the	   S4	   segment.	   	   CaV1.2	   selectivity	   for	   Ca2+	   is	   achieved	   by	   S5-­‐S6	   pore	  
segment	   on	   each	   repeat	   [91].	   	   	  Macroscopic	   ICa,L	   through	   the	   CaV1.2	   is	   defined	   as	  
current	  I=i*N*Po	  [8].	  	  LTCC	  initiates	  calcium	  induced	  calcium	  release	  (CICR)	  by	  Ca2+	  
through	   the	   LTCC	   binding	   nearby	   RyR2	   on	   the	   SR	   Ca2+	   store	   [35].	   	   Relaxation	   is	  
mediated	   through	   clearance	   of	   the	   cytosolic	   Ca2+	   by	   SR	   re-­‐uptake,	   NCX,	   and	  
Ca2+ATPase.	   	   In	   order	   to	   maintain	   Ca2+	   homeostasis,	   LTCC	   inactivate	   by	   voltage	  
dependence	  (VDI)	  or	  Ca2+	  dependence	  (CDI).	  	  Loss	  of	  function	  of	  either	  inactivation	  
can	   lead	   to	   increased	   pathological	   cytosolic	   Ca2+	   resulting	   in	   prolonged	   action	  
potentials	  that	  may	  cause	  arrhythmias	  [41,	  55].	  	  Kinases	  enhance	  LTCC	  function	  by	  
shifting	   the	   activation	   curve	   more	   negative	   and	   increasing	   the	   frequency	   and	  
duration	   of	   channel	   openings.	   	   The	   CaV1.2	   carboxyl-­‐terminus	   is	   a	   substrate	   for	  
kinase	   association	   and	   regulation	   [59,	   64,	   66-­‐68].	   	   Cardiac	   CaV1.2	   channels	   are	  
expressed	   as	   full	   length	   ~250kDa	   protein	   or	   a	   truncated	   ~190	   kDa	   [59].	   	   CaV1.2	  
carboxyl-­‐terminal	   deletion	   studies	   show	   increased	   4-­‐6	   fold	   increase	   in	   IBa,L	   when	  
~70%	   of	   the	   CaV1.2	   channel	   is	   truncated[76].	   The	   remaining	   CaV1.2	   carboxyl-­‐
terminus	   was	   later	   shown	   to	   re-­‐associate	   with	   the	   CaV1.2	   proximal-­‐carboxyl-­‐
terminus	  (PCT)	  to	  recapitulate	  block	  of	  IBa,L	  similar	  to	  full	  length	  CaV1.2	  [1].	  	  	  
The	  contribution	  of	  LTCC	  to	  cardiomyocyte	  cytosolic	  Ca2+	  homeostasis	  on	  a	  
beat-­‐to-­‐beat	  basis	  has	  been	  an	  area	  of	  intense	  focus[5,	  6,	  25,	  31,	  34,	  35,	  38,	  40,	  45,	  
57].	  	  The	  LTCC	  multiple	  roles	  include	  Ca2+	  signaling	  gene	  regulation	  that	  can	  set	  the	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diastolic	  resting	  Ca2+	  between	  beats.	  	  The	  goal	  of	  this	  thesis	  is	  to	  examine	  the	  auto-­‐
regulatory	   function	   of	   CaV1.2	   carboxyl-­‐terminus.	   	   The	   function	   of	   LTCC	   channel	  
segments	   such	   as	   the	   CaV1.2	   carboxyl-­‐terminus	   is	   an	   active	   ongoing	   field	   of	  
research[63].	   	   Although,	   LTCC	   channels	   have	   been	   studied	   extensively	   in	  
heterologous	   over-­‐expression	   systems,	   the	   number	   of	   studies	   on	   how	   the	   distal	  
carboxyl-­‐terminus	   of	   the	   CaV1.2	   channel	   regulates	   function	   in	   a	   native	   system	   is	  
limited.	  	  
	  
1.9 Dissertation Overview 
In	  Summary,	  the	  CaV1.2-­‐DCT(1821-­‐2171)	  blocks	  LTCC	  Ba2+	  currents	  (IBa,L)	  in	  
heterologous-­‐expression	   systems	   [1,	   76,	   92].	   	   Early	   studies	   of	   deletion	   analysis	   of	  
CaV1.2	   expressed	   in	   oocytes	   and	   HEK	   cells	   promoted	   the	   current	   view	   that	   DCT	  
inhibits	  LTCC	  current[76,	  77].	   	  These	  previous	  studies	  showed	  that	  the	  shorter	  the	  
CaV1.2	   channel	   truncation,	   the	   larger	   the	   resulting	   current	   [92].	   	   Subsequently,	  
Hulme	  et	  al.	  showed	  that	  co-­‐expression	  of	  DCT	  with	  truncated	  CaV1.2	  reduced	  IBa,L	  
[1].	   	   Moreover,	   DCT	   re-­‐associates	   with	   CaV1.2	   near	   the	   CB/IQ	   domain	   on	   the	  
proximal	  carboxyl	  terminus	  (PCT).	  	  It	  is	  notable	  that	  the	  DCT	  interaction	  on	  CaV1.2	  
PCT	  site	  is	  juxtaposed	  to	  CaM	  interaction	  domains[93].	   	  Therefore	  it	  is	  plausible	  to	  
suggest	  that	  CaM	  may	  interact	  with	  DCT-­‐LTCC	  function	  (Figure	  1.6).	  	  To	  date,	  there	  
are	   no	   reports	   of	   DCT	   effects	   on	   ICa,L	   in	   HEK	   293	   studies,	   	   nor	   is	   there	   a	  
demonstration	  of	  DCT	  effects	  on	  LTCC	  function	  in	  cardiomyocytes	  [94].	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The	  overlying	  goal	  of	  this	  thesis	  is	  to	  examine	  the	  hypothesis	  that	  DCT	  is	  an	  
important	  mediator	  of	   cell	   Ca2+	  homeostasis	   in	   cardiomyocytes	   and	   functions	   in	   a	  
calcium	   concentration	   dependent	  manner.	   	   The	   dissertation	   attempts	   to	   elucidate	  
modulation	   of	   L-­‐type	   calcium	   currents	   based	   on	   findings	   suggesting	   the	   cleaved	  
CaV1.2(1821-­‐2171)	  distal	  c-­‐terminal	  domain	  of	  the	  L-­‐type	  calcium	  channel	  can	  serve	  
as	   a	   direct	   channel	   modulator	   and	   transcription	   factor[1,	   23,	   24,	   75,	   76,	   95].	   My	  
overall	   hypothesis	   is	   that	   L-­‐type	   calcium	   currents	   contribute	   to	   dynamic	   Cav1.2	  
distal	   carboxyl-­‐terminus	   (DCT)	   ICa,L	   block,	   acting	   as	   a	   reverse	   use-­‐dependent	  
inhibitor	  that	  increases	  current	  block	  under	  relatively	  low	  Ca2+	  (Figure	  1.6).	  
My	  simplified	  cartoon	  represents	  (Figure	  1.6)	  physiological	  conditions	  of	  the	  
CaV1.2	  channel	  in	  ventricular	  myocytes.	  	  CaV1.2	  is	  the	  main	  pore	  forming	  subunit	  
with	  a	  predicted	  mass	  of	  250kD	  and	  the	  exact	  length	  varies	  with	  species	  and	  splice	  
variants	  [96].	  	  The	  large	  ~665	  amino	  acid	  CaV1.2	  carboxyl	  terminus	  is	  located	  in	  the	  
cytosolic	  space	  [25].	  	  The	  cartoon	  does	  not	  depict	  accessory	  proteins	  such	  as	  CaVβ2a	  
or	  α2δ	  fo	  simplicity.	  	  Spectroscopic	  studies	  of	  the	  related	  skeletal	  muscle	  L-­‐type	  Ca2+	  
channel	  isoform,	  CaV1.1,	  is	  cleaved	  at	  a	  site	  on	  the	  carboxyl	  terminus	  [1].	  CaV1.2	  
distal	  carboxyl-­‐terminus	  (DCT)	  has	  a	  predicted	  mass	  of	  ~37	  kDa	  [1].	  	  Therefore,	  the	  
CaV1.2	  remaining	  mass	  is	  <	  200	  kDa	  in	  the	  cardiomyocyte	  complex.	  The	  CaV1.2	  
length	  is	  reported	  as	  ~190	  kDa	  in	  human	  [97].	  	  Antibodies	  against	  full	  length	  CaV1.2	  
show	  singlets	  and	  doublets,	  but	  some	  of	  the	  literature	  figures	  are	  incomplete	  
because	  the	  blots	  were	  cut	  off	  either	  above	  190	  or	  below	  250	  kDa	  limiting	  the	  data	  
description.	  	  	  	  The	  model	  starts	  with	  the	  channel-­‐closed	  in	  low	  membrane	  potential	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hyperpolarized	  approximately	  -­‐80	  mV	  (left	  top).	  	  Middle	  panel	  Po	  diagram	  (Figure	  
1.5),	  NPo	  is	  relatively	  low	  and	  Ca2+	  driving	  force	  is	  relatively	  high.	  	  Apo-­‐CaMs	  (Ca2+	  
free	  form	  of	  CaM)	  is	  constitutively	  pre-­‐associated	  with	  the	  channel	  and	  up	  to	  two	  
CaMs	  can	  bind	  to	  the	  CaV1.2	  carboxyl-­‐terminus	  on	  the	  Pre-­‐IQ	  C-­‐region	  and	  the	  IQ	  
domain	  respectively[98].	  	  In	  non-­‐physiological	  conditions	  where	  DCT	  and/or	  CaM	  is	  
over-­‐expressed	  in	  the	  cardiomyocytes,	  CaM	  may	  functionally	  compete	  with	  proteins	  
that	  can	  interact	  with	  the	  CaV1.2	  proximal	  carboxyl-­‐terminus.	  	  We	  tested	  this	  in	  our	  
previous	  paper	  demonstrating	  with	  biochemistry	  and	  electrophysiology	  that	  Rem,	  a	  
small	  GTPase	  could	  interact	  with	  the	  CaV1.2	  PCT	  and	  then	  be	  functionally	  displaced	  
by	  CaM.	  	  We	  noted	  a	  recovery	  from	  zero	  current,	  the	  main	  effect	  of	  Rem	  co-­‐
expression	  with	  channel,	  and	  a	  slowing	  of	  CDI	  which	  implies	  Rem	  may	  functionally	  
compete	  with	  CaM[60].	  	  I	  propose	  a	  general	  concept	  that	  Cav1.2	  has	  many	  binding	  
partners	  and	  those	  proteins	  may	  have	  binding	  partners.	  	  Moreover,	  if	  channels	  are	  
in	  clusters	  they	  will	  gate	  faster	  than	  low-­‐density	  clusters	  or	  individual	  channels	  
suggesting	  a	  cooperative	  gating.	  	  Now,	  take	  the	  well	  described	  interaction	  of	  a	  Ca2+	  
sensing	  protein	  CaM	  as	  tool	  to	  functionally	  dissect	  proteins	  dynamically	  interacting	  
with	  the	  proximal	  carboxyl-­‐terminus	  in	  cardiomyocytes.	  	  Rem	  demonstrated	  a	  case	  
for	  using	  CaM	  as	  a	  functional	  readout	  of	  association	  backed	  up	  by	  biochemistry	  data.	  	  
Building	  on	  the	  concept	  of	  CaM	  functional	  displacement	  of	  CaV1.2	  PCT	  interacting	  
proteins,	  I	  will	  test	  if	  excess	  CaM	  functionally	  disrupts	  DCT	  current	  inhibition	  in	  
cardiomyocytes	  and	  HEK	  over-­‐expression	  systems.	  I	  will	  use	  a	  similar	  analysis	  from	  
the	  Rem	  experiment	  predicting	  DCT	  will	  slow	  CDI.	  	  Since	  CaM	  is	  a	  localized	  channel	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Ca2+	  sensor,	  I	  postulate	  that	  DCT	  functional	  inhibition	  maybe	  affected	  by	  cytosolic	  
Ca2+	  concentration.	  	  Ba2+	  used	  as	  the	  charge	  carrier	  in	  electrophysiology	  experiment	  
with	  Ca2+	  buffering	  EGTA	  in	  the	  pipette	  solution	  will	  test	  a	  nominal	  Ca2+	  
environment	  when	  DCT	  and	  CaM	  are	  over-­‐expressed.	  	  I	  predict	  DCT	  will	  functionally	  
inhibit	  IBa,L	  as	  published	  in	  previous	  literature	  and	  the	  co-­‐expression	  of	  CaM	  to	  
interrupt	  DCT	  current	  block.	  	  Now	  to	  test	  the	  effect	  of	  increased	  Ca2+	  on	  DCT	  
inhibition	  of	  ICa,L,	  I	  will	  use	  physiological	  bath	  solutions.	  	  As	  Ca2+	  is	  readily	  available,	  
I	  predict	  the	  pre-­‐associated	  CaMs	  will	  bind	  Ca2+,	  change	  conformation,	  and	  reduce	  
the	  ability	  of	  DCT	  to	  functionally	  inhibit	  the	  channel.	  	  However,	  in	  intact	  myocytes	  I	  
postulate	  that	  DCT	  may	  lower	  NPo	  at	  negative	  potential.	  	  Whole	  cell	  patch	  clamp	  ICa,L	  
are	  relatively	  small	  at	  peak	  current,	  assessing	  current	  at	  low	  voltages	  requires	  a	  
different	  approach	  to	  test	  this	  hypothesis.	  	  I	  will	  use	  intact	  cardiomyocytes	  and	  
assess	  the	  resting	  diastolic	  Ca2+	  using	  a	  calcium	  ratio	  metric	  dye.	  	  The	  cells	  can	  then	  
be	  electrically	  stimulated	  at	  different	  frequencies	  to	  test	  a	  range	  of	  systolic	  Ca2+,	  as	  
pacing	  frequency	  increases	  so	  does	  diastolic	  Ca2+.	  	  As	  NPo	  increases,	  diastolic	  Ca2+	  
increases,	  and	  DCT	  inhibition	  is	  relieved.	  	  	  	  	  
1.9.1 Regulation of CaV1.2 function by DCT and CaM (in Chapter 3) 
Specific Aim 1: Establish DCT block on Ica,L in a reconstituted system. 
Rationale: The LTCC distal carboxyl-terminus (DCT) is proteolytically cleaved, and re-
associates with the LTCC complex to regulate Ca2+ channels[1].  DCT reduces LTCC 
barium current (IBa,L) in reconstituted complexes, and mediated by the fight or flight 
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response[64];  yet the contribution of DCT to ICa,L in reconstituted systems is 
unexplored.  This study examines the contribution of DCT to LTCC function in the HEK 
model. 
Specific Aim 2: Functionally compete with DCT block on Ica,L in a reconstituted system. 
Rationale: CaM is a calcium sensor pre-associated with the PCT on the LTCC, and DCT 
re-associates with the LTCC complex to regulate Ca2+ channels[1, 76, 77].  CaM partially 
restores PCT associated Rem block LTCC calcium current (ICa,L) in reconstituted 
complexes, and slows the calcium dependent inactivation kinetics.  Over-expression of 
CaM may functionally compete with DCT block to restore LTCC IBa,L and ICa,L. in 
reconstituted systems.  This study examines the contribution of CaM to functional DCT 
block  on LTCC function in the HEK model. 
 
1.9.2 CaV1.2-DCT as a reverse use dependent inhibitor (in Chapter 4) 
Specific Aim 1: Establish DCT block on IBa,L and ICa,L in a native cardiomyocyte system. 
Rationale: The LTCC distal Carboxyl-terminus (DCT) is proteolytically cleaved, and re-
associates with the LTCC complex to regulate Ca2+ channels[1].  DCT reduces LTCC 
barium current (IBa,L) in reconstituted complexes;  however the contribution of DCT to 
IBa,L and ICa,L in native cardiomyocyte systems is unexplored.  This study examines the 
contribution of DCT to LTCC function in the cardiomyocyte model. 
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Specific Aim 2: Functionally compete with DCT block on IBa,L and ICa,L L in a 
cardiomyocyte. 
Rationale: CaM is a calcium sensor pre-associated with the PCT on the LTCC, and DCT 
re-associates with the LTCC complex to regulate Ca2+ channels[1, 76, 77].  CaM partially 
restores PCT associated Rem block LTCC calcium current (ICa,L) in reconstituted 
complexes, and slows the calcium dependent inactivation kinetics.  Over-expression of 
CaM may functionally compete with DCT block to restore LTCC IBa,L and ICa,L. in a 
native cardiomyocyte system.  This study examines the contribution of CaM to functional 
DCT block on LTCC function in the native cardiomyocyte model. 
Specific Aim 3: Establish DCT block as a function of low to high frequency electrical 
pacing of the cardiomyocytes in-vitro. 
Rationale: Increasing diastolic calcium is sufficient to induce pathological hypertrophy, 
reduced contraction, and arrhythmias.  Electrical pacing depolarized the membrane 
opening LTCC increasing cytosolic Ca2+ concentration beat to beat.  As frequency of 
electrical stimulation is reduced, LTCC contribution to the cytosol is decreased.  Since 
DCT does not block ICa,L but does IBa,L  in whole cell Ca2+ buffered patch clamp 
recordings, I postulate that cytosolic Ca2+ is high when Ca2+ currents are recorded and 
cytosolic Ca2+ is nominally low when Ba currents are recorded. Over-expression of DCT 
may functionally block at very low cytosolic Ca2+ in an intact native cardiomyocyte 
system.  This study examines the contribution of cytosolic Ca2+ to functional DCT block 









Table 1.1 List of Abbreviations  
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Figure	   1.1	   L-­‐type	   Calcium	   channels	   are	   part	   of	   a	   voltage	   gated	  
superfamily.	   	   	   The	   table	   represents	   a	   brief	   overview	   of	   channels	   and	  
function,	  for	  complete	  details	  see	  excellent	  reviews	  from	  Catterall	  [2].	   	  The	  
gene	  CACNA1C	  encodes	  for	  the	  protein	  CaV1.2.	  	  L-­‐type	  calcium	  channels	  are	  
high	   voltage	   activated	   (HVA)	   channels.(highlighted	   box).	   	   CaV1.2	   channels	  
are	  expressed	  in	  heart,	  smooth	  muscle,	  neurons,	  and	  endocrine	  cells.	  	  CaV1.2	  
is	  the	  predominant	  protein	  expressed	  in	  ventricular	  cardiomyocytes.	  CaV1.2	  
triggers	   excitation-­‐contraction	   coupling	   (EC-­‐coupling)	   and	   can	   act	   as	   a	  
transcription	  factor.	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Figure	   1.2	   Structure	   of	   CaV1.2.	   	   	   CaV1.2	   is	  made	   up	   of	   6	   transmembrane	  
segments	   with	   4	   repeats.	   	   Segment	   4	   (S4)	   is	   the	   voltage	   sensor	   and	   the	  
hairpin	   loop	   between	   S5-­‐S6	   confers	   ion	   selectivity	   for	   the	   pore.	   	   CaV1.2	  
forms	  a	  complex	  with	  many	  interaction	  partners,	  however	  CaVβ	  subunit	  co-­‐
expression	  with	  the	  channel	  is	  sufficient	  for	  recording	  ICa,L	  and	  IBa,L.	   	  DCT	  is	  
thought	   to	   be	   associated	   with	   PCT	   through	   electrostatic	   interaction.	  	  
Ser1700	  and	  Ser1928	  are	  described	  substrates	  for	  kinase	  phosphorylation.	  





Figure 1.3 Fundamental components of Excitation contraction coupling 
	   	  
Figure	  1.3	  Fundamental	  components	  of	  excitation	  contraction	  coupling.	   	  	  A	  
simplified	   picture	   of	   the	   CICR	   with	   the	   major	   components	   for	   excitation-­‐
contraction	  and	   relaxation.	   	   CaV1.2	   channel	   (LTCC)	   opens	  upon	  membrane	  
depolarization.	   	   Ca2+	   goes	   through	   the	   channel	   and	   binds	   RyR2	   on	   the	  
Sarcoplasmic	   reticulum	   (SR),	   globally	   releasing	   Ca2+	   into	   the	   cytosol.	   	   As	  
cytosolic	   Ca2+	   concentrations	   increase,	  Ca2+	   binds	  Troponin	  C	   	   followed	  by	  
contraction.	  	  Ca2+	  is	  cleared	  from	  the	  cytosol	  through	  multiple	  actions.	  	  Most	  
notably,	  Ca2+	   is	  extruded	  by	  NCX,	  Ca2+-­‐ATPase,	  and	  by	  SR	  Ca2+	  re-­‐uptake	  to	  




Figure	   1.4	   Relationship	   of	   Action	   potential	   to	   Po	   and	   Ca2+	   driving	   force.	   	   When	  
membrane	   potential	   is	   negative,	   CaV1.2	   channel	   Po	   (blue)	   is	   low	   and	   Ca2+	  
electrochemical	  driving	  force	  is	  high.	  I	  propose	  DCT	  lowers	  Po	  comparatively.	  	  As	  Po	  











Figure	   1.5	   CaV1.2	   Proximal	   and	   Distal	   Carboxyl-­‐terminus.	   	   CaV1.2	   proximal	  
carboxyl-­‐terminus	   	   (PCT)	   contains	   the	   IQ	   domain	   with	   CaM	   pre-­‐associated.	  	  	  	  
DCT	  can	  functionally	  re-­‐associate	  with	  the	  channel	  to	  inhibit	  IBa,L	  in	  HEK	  cells	   .	  	  	  	  
PCT	  and	  DCT	  are	  substrates	  for	  kinase	  regulation	  at	  Ser1701	  and	  Ser1928.	  	  DCT	  
contains	  an	  inhibitory	  domain	  from	  amino	  acids	  2024-­‐2171	  in	  rabbit	  sequence.	  	  	  
 
 
Figure 1.5  CaV1.2 Proximal and Distal Carboxyl-terminus.    
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Figure	   1.6	   Proposed	  model	   of	   DCT	   function.	   	   	   DCT	  blocks	   CaV1.2	  Ba2+	   current	   in	  
cardiomyocytes	   and	  HEK	   293	   cells.	   	   CaM	   (tethered	   black	   circles)	   over-­‐expression	  
completely	   reverses	   DCT	   functional	   inhibition	   of	   Ba2+	   current.	   	   When	   membrane	  
potential	   is	   negative,	   CaV1.2	   channel	   Po	   is	   low,	   and	   addition	   of	   DCT	   lowers	   Po	  
comparatively.	   	   As	   the	   channel	   opens	   and	   Ca2+	   enters	   the	   cytosol	   increasing	  
concentration	   around	   the	   channel	   and,	   DCT	   no	   longer	   functionally	   inhibits	   the	  
channel	  (bottom	  right).	   	  If	  Ca2+	  remains	   low	  and	  Ba2+	  is	  used	  as	  the	  charge	  carrier,	  
















Chapter 2: Materials and methods 
	  
2.1 HEK cell culture 
	   Cells	  were	  maintained	  at	  37°	  Celsius	  and	  5%	  CO2.	  Cells	  were	  split	  when	  the	  
division	  reached	  70%	  confluence	  in	  10	  cm	  tissue	  culture	  plate.	  	  Cells	  were	  washed	  
with	  PBS,	  and	  then	  incubated	  with	  5	  mL	  of	  trypsin	  for	  3	  minutes.	  	  Addition	  of	  5mL	  
10%	  FBS	  tissue	  culture	  media	  neutralized	  the	  trypsin.	  	  Cells	  were	  collected	  and	  
centrifuged	  for	  3	  minutes	  at	  500	  rpm.	  	  The	  supernatant	  was	  removed	  and	  10mL	  of	  
fresh	  media	  was	  added	  to	  the	  cell	  pellet.	  	  5-­‐10	  drops	  of	  the	  re-­‐suspended	  cells	  were	  
added	  to	  new	  10	  cm	  tissue	  culture	  plates	  containing	  10mL	  of	  fresh	  tissue	  culture	  
media	  with	  10%	  FBS.	  	  Cells	  were	  not	  split	  less	  than	  three	  days	  at	  a	  time	  and	  new	  
cells	  were	  thawed	  once	  passage	  number	  exceeded	  20	  to	  maintain	  a	  range	  in	  
heterologous	  transfection	  efficiency.	  	  	  
2.2 E18 primary cell isolation 
ICR	  (outbred	  Charles	  Rivers	  mice,	  CD-­‐1®)	  mice	  were	  housed	  in	  a	  pathogen-­‐free	  
facility	  and	  handled	  in	  accordance	  with	  standard	  use	  protocols,	  animal	  welfare	  
regulations,	  and	  the	  NIH	  Guide	  for	  the	  Care	  and	  Use	  of	  Laboratory	  Animals.	  All	  
protocols	  were	  approved	  by	  the	  University	  of	  Kentucky	  Institutional	  Animal	  Care	  
and	  Use	  Committee	  (IACUC	  protocol	  #00963M).	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Fetal	  ventricular	  cardiomyocytes	  were	  isolated	  as	  described	  previously[99].	  	  	  Timed	  
pregnant	  dams	  of	  embryonic	  day	  16-­‐19	  (E16-­‐19)	  were	  anesthetized	  with	  ketamine	  
(90mg/kg)	  +	  xylazine	  (10mg/kg)	  intraperitoneal	  injected	  .	  	  Litters	  were	  removed.	  	  
Fetuses	  were	  decapitated	  and	  hearts	  excised.	  While	  under	  anesthesia	  the	  dam	  was	  
euthanatized	  by	  heart	  excision.	  	  Below	  outlines	  the	  isolation	  in	  detail. 
2.2.1	  Solutions	  
1.	  	  50	  mL	  1xPBS+25microL	  2M	  MgCl2,	  filter	  with	  0.45micron	  filter	  (white)	  	  2.	  	  Add	  
10micrograms	  of	  Worthington	  Collagenase	  II	  to	  20mL	  of	  PBS+MgCl2.	  	  Add	  10	  mL	  to	  
a	  10	  mL	  syringe	  and	  add	  a	  0.2	  micron	  filter.	  	  3.	  	  Add	  2.5mL	  freshly	  thawed	  FBS	  to	  a	  
50mL	  tube	  and	  bring	  to	  50mL	  volume	  with	  5%	  FBS/DMEM	  
2.2.2	  Isolation	  Protocol	  
Place	  embryo	  sac	  containing	  pups	  in	  50mL	  tube	  with	  ~5-­‐10mL	  of	  PBS	  +	  MgCl2	  (250	  
microL	  of	  2mM	  MgCl2	  added	  to	  500mL	  PBS).	  	  Extract	  pups,	  remove	  all	  from	  
embryonic	  sac.	  	  In	  sequence,	  decapitate,	  cut	  down	  chest	  from	  neckline,	  spread	  with	  
forceps	  and	  press	  cavity	  until	  heart	  pops	  up,	  pull	  heart	  and	  place	  in	  separate	  dish	  
with	  ~3mL	  PBS+MgCl2.	  	  Grab	  atria	  or	  aorta	  with	  forceps	  and	  cut	  away	  with	  scissors.	  	  
Press	  hearts	  to	  push	  any	  remaining	  blood	  out	  of	  the	  vessels	  or	  arteries	  and	  place	  
ventricle	  in	  15mL	  tube	  with	  ~	  10mL	  of	  PBS+MgCl2.	  	  Spin	  ~	  5min	  at	  500	  rpm.	  	  Re-­‐
suspend	  in	  ~	  1mL	  of	  filtered	  Collagenase.	  	  Cut	  the	  tip	  off	  a	  1000	  μL	  tip	  and	  transfer	  
the	  pellet	  to	  a	  culture	  dish	  lid	  with	  ~	  1	  mL	  of	  filtered	  Collagenase	  II	  (Worthington).	  	  
Tear	  the	  hearts	  apart	  using	  forceps.	  	  	  Transfer	  hearts	  back	  into	  the	  15mL	  tube	  and	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bring	  to	  10mL	  volume	  with	  filtered	  Collagenase.	  	  Set	  tube	  on	  its	  side	  in	  the	  37	  
degree	  incubator	  for	  10	  min,	  then	  spin	  down	  for	  ~5	  minutes	  at	  500	  rpm.	  	  Re-­‐
suspend	  in	  fresh	  filtered	  Collagenase.	  	  Cut	  the	  tip	  off	  a	  1000	  μL	  tip	  and	  transfer	  the	  
pellet	  to	  a	  culture	  dish	  lid	  with	  ~	  1	  mL	  of	  filtered	  Collagenase.	  	  Bring	  to	  10mL	  
volume	  with	  filtered	  Collagenase.	  	  Set	  tube	  on	  its	  side	  in	  the	  37°	  incubator	  for	  10	  
min,	  then	  spin	  down	  for	  ~5	  at	  500	  rpm.	  	  Based	  on	  pellet	  size,	  re-­‐suspend	  with	  5-­‐10	  
mL	  of	  10%	  FBS/DMEM.	  	  Break	  apart	  the	  pellet	  using	  a	  3mL	  syringe	  +	  18	  gauge	  
needle.	  	  Setup	  a	  24	  well	  plate	  with	  pre-­‐treated	  coverslips	  (Poly-­‐L,	  Lamimin,	  or	  
Fibronectin	  for	  at	  least	  30	  min	  under	  UV	  light).	  	  Add	  0.5	  mL	  of	  media	  in	  each	  well	  
and	  use	  serological	  pipette	  to	  submerse	  all	  coverslips.	  	  Swirl	  plate	  to	  rinse	  coverslips	  
well.	  	  Remove	  media	  and	  add	  500	  μL	  of	  fresh	  10%	  FBS/DMEM	  to	  each	  well.	  	  Place	  
plate	  in	  incubator	  (This	  step	  can	  be	  done	  during	  the	  second	  10	  minute	  incubation	  
with	  Collagenase).	  	  To	  the	  first	  3	  wells,	  add	  1	  drop,	  then	  2	  drops	  to	  the	  second	  well,	  
and	  3	  drops	  to	  the	  third	  well.	  	  Compare	  wells	  under	  the	  microscope	  and	  choose	  the	  
desired	  plating	  density.	  	  The	  method	  described	  produces	  the	  best	  results.	  	  For	  
electrophysiology	  experiments,	  plate	  ~	  5000	  cell	  per	  35mm	  dish.	  	  Plating	  with	  less	  
cells	  will	  result	  in	  poor	  transfection	  efficiency.	  	  To	  account	  for	  this	  variation,	  I	  plated	  
half	  the	  wells	  with	  one	  drop	  and	  the	  other	  half	  of	  the	  wells	  with	  2	  drops.	  	  Plating	  >	  





2.3 Adult ventricular myocyte isolation 
Single	  adult	  ventricular	  myocytes	  were	  isolated	  using	  a	  Alliance	  for	  Cellular	  
Signaling	  protocol	  PP00000125	  with	  modifications[24].	  Four	  to	  six	  month	  old	  
female	  ICR	  mice	  were	  anesthetized.	  	  	  Chest	  was	  opened	  to	  expose	  the	  lungs	  and	  
heart.	  	  The	  heart	  was	  excised,	  hung	  on	  a	  blunted	  needle	  in	  less	  than	  1	  min,	  then	  
retrogradely	  perfused	  at	  3	  mL/min	  at	  37°C	  for	  4	  to	  8	  minutes	  with	  a	  Ca2+-­‐free	  
bicarbonate	  based	  perfusion	  buffer	  containing	  (in	  mmol/L)	  NaCl	  113;	  KCl	  4.7;	  
KH2PO4	  0.6;	  MgSO4	  1.2;	  NaH2PO4	  0.6;	  glucose	  5.5;	  NaHCO3	  12;	  KHCO3	  10;	  HEPES	  10;	  
phenol	  red	  0.032;	  2,3-­‐butanedione	  mon-­‐	  oxime	  10;	  and	  taurine	  30.	  Before	  the	  heart	  
was	  perfused,	  the	  perfusion	  buffer	  was	  gassed	  with	  95%	  O2/5%	  CO2	  for	  at	  least	  30	  
minutes.	  Enzymatic	  digestion	  began	  using	  0.25	  mg/mL	  liberase	  blendzyme	  (Roche),	  
and	  12.5	  μmol/L	  CaCl2	  was	  added	  to	  the	  perfusion	  buffer	  for	  approximately	  10-­‐15	  
minutes	  until	  the	  heart	  was	  swollen	  and	  pale	  in	  color.	  The	  heart	  was	  then	  cut	  from	  
the	  cannula.	  Ventricular	  tissue	  was	  placed	  in	  a	  dish	  with	  enzyme	  buffer	  and	  gently	  
dissociated	  for	  several	  minutes.	  After	  the	  addition	  of	  stop	  buffer	  (perfusion	  buffer	  
containing	  10%	  FBS	  and	  12.5	  μmol/L	  CaCl2),	  dissociation	  continued	  until	  large	  
pieces	  of	  heart	  tissue	  were	  gently	  dispersed	  into	  the	  cell	  suspension.	  Cells	  were	  
allowed	  to	  sediment	  by	  gravity	  for	  10	  minutes	  followed	  by	  centrifugation	  at	  500	  
rpm	  for	  1-­‐3	  minutes.	  Cells	  were	  re-­‐suspended	  in	  perfusion	  buffer	  containing	  5%	  
FBS/DMEM	  and	  12.5	  μmol/L	  CaCl2.	  External	  Ca2+	  was	  added	  in	  four	  segments	  to	  the	  
solution	  with	  a	  final	  concentration	  of	  2.0	  mmol/L.	  Only	  rod-­‐shaped,	  square	  ended,	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quiescent	  myocytes	  with	  clear	  striations	  were	  selected	  for	  current	  recordings	  or	  
Ca2+	  imaging.	  
2.4  Plasmids 
Full	  length	  CaV1.2	  plasmid	  (provided	  by	  Dr.	  T.	  Kamp,	  University	  of	  Wisconsin)	  was	  
identical	  to	  the	  cloned	  full-­‐length	  rabbit	  cardiac	  α1C-­‐subunit[100,	  101]	  except	  for	  
alternative	  splicing	  in	  domain	  IV	  S3[101].	  	  Rat	  CaVβ2a	  plasmid	  (provided	  by	  Dr.	  E.	  
Perez-­‐Reyes,	  University	  of	  Virginia)[10]	  contains	  two	  cysteine	  residues	  	  within	  the	  
D1	  domain	  associated	  with	  palmitoylation.	  CaM1234	  was	  provided	  by	  David	  T.	  Yue	  
(Johns	  Hopkins	  University),	  and	  CaV1.2Δ1801	  was	  provided	  by	  Henry	  Colecraft	  
(Columbia	  University).	  
2.5 Lipofectamine transfection 
HEK-­‐293	  cells	  were	  transiently	  transfected	  with	  plasmids	  4-­‐6	  hours	  using	  
Lipofectamine®	  2000	  transfection	  (Invitrogen	  Corporation),	  then	  recordings	  were	  
performed	  24-­‐48	  hours	  after	  transfection,	  as	  previously	  described	  [102].	  
Transfected	  cells	  were	  identified	  by	  the	  expression	  of	  eGFP. 
2.6 Ca2+ imaging 
E18	  fetal	  mouse	  cardiomyocytes	  were	  used	  24-­‐72	  hours	  after	  
Lipofectamine®	  2000	  transfection	  (Invitrogen	  Corporation).	  	  Myocytes	  plated	  on	  
Poly-­‐L-­‐Lysine	  25mm	  square	  glass	  coverslips	  were	  incubated	  with	  2micoM	  of	  freshly	  
mixed	  Fura-­‐2,	  AM	  (Molecular	  Probes,	  F-­‐1221,	  from	  stock	  2.5mM	  in	  DMSO)	  +	  10%	  
FBS	  media	  for	  8	  minutes	  at	  37°C	  without	  Pluronic	  (as	  sometimes	  used	  to	  aid	  adult	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myocyte	  Fura-­‐2	  loading).	  	  Coverslips	  were	  transferred	  to	  a	  custom-­‐designed	  
microscope	  chamber	  system	  containing	  physiological	  salt	  solution	  with	  1.8mM	  
CaCl2.	  	  Transfected	  cells	  were	  identified	  by	  the	  eGFP	  or	  eGFP	  fused	  CaV1.2	  (1821-­‐
2171)	  at	  the	  N-­‐term.	  	  Cells	  were	  measured	  initially	  for	  20	  seconds	  without	  pacing,	  
and	  then	  paced	  at	  1Hz,	  2Hz,	  3Hz,	  0.5	  Hz,	  and	  0Hz	  for	  20-­‐60	  seconds	  at	  each	  
frequency.	  	  Diastolic	  F340/F380	  (F/Fo	  )	  ratios	  were	  determined	  using	  Clampfit	  9.2.	  	  	  
Ca2+	  calibrations	  were	  performed	  as	  in	  reference	  [103].	  	  All	  recordings	  were	  
performed	  at	  room	  temperature	  (20–22°C)	  using	  IonOptix	  Myocyte	  Calcium	  
Recording	  System,	  Myopacer	  Field	  Stimulator,	  and	  IonWizard	  4.4	  revision	  13	  
(IonOptix	  LLC,	  Milton,	  MA).	  	  I	  used	  unpaired	  Students	  t-­‐test	  to	  test	  for	  significance	  
between	  control	  and	  experimental	  groups.	  
  
2.7 Electrophysiology 
Transfected	  cells	  were	  identified	  by	  the	  expression	  of	  eGFP.	  The	  whole	  cell	  
configuration	  of	  the	  patch-­‐clamp	  technique	  was	  used	  to	  measure	  ionic	  current.	  
Patch	  electrodes	  with	  resistances	  of	  1–2.5	  MΩ	  contained	  pipette	  solution	  consisting	  
of:	  (in	  mM)	  110	  K-­‐gluconate	  (or	  110	  TEA-­‐Cl),	  40	  CsCl,	  3	  EGTA,	  1	  MgCl2,	  5	  Mg-­‐ATP,	  
and	  5	  HEPES,	  pH	  to	  7.36	  with	  CsOH.	  	  The	  bath	  solution	  for	  HEK	  cells	  consisted	  of	  (in	  
mM)	  130	  (or	  112.5)	  CsCl,	  2.5	  (or	  30)	  BaCl2	  or	  CaCl2,	  1	  MgCl2,	  10	  
tetraethylammonium-­‐Cl,	  and	  5	  HEPES,	  5	  glucose,	  pH	  7.4	  with	  CsOH.	  	  	  For	  fetal	  
ventricular	  myocytes,	  the	  physiological	  salt	  solution	  (PSS)	  contained	  140	  NaCl,	  1.8	  
CaCl2,	  1	  MgCl2,	  5.4	  KCl,	  10	  glucose,	  and	  10	  HEPES,	  pH	  7.4.	  The	  Na-­‐free	  bath	  was	  150	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N-­‐methyl-­‐D-­‐glucamine,	  2.5	  BaCl2	  (or	  CaCl2),	  1MgCl2,	  10	  HEPES,	  10	  glucose,	  and	  5	  4-­‐
aminopyridine,	  pH	  7.4.	  Signals	  were	  amplified	  with	  an	  Axopatch	  200B	  amplifier,	  
with	  series	  resistance	  compensation,	  and	  captured	  at	  333	  kHz	  A/D	  system	  (Axon	  
Instruments,	  Union	  City,	  CA).	  	  For	  HEK	  293	  cells,	  current-­‐voltage	  curves	  were	  
generated	  by	  voltage	  clamp	  protocols	  consisting	  of:	  Vhold=	  	  -­‐80	  mV	  followed	  by	  320	  
ms	  Vtest	  pulse	  ranging	  from	  -­‐80	  mV	  to	  +80	  mV	  in	  5	  mV	  increments	  (Figure	  2.1).	  	  For	  
myocytes,	  current-­‐voltage	  curves	  were	  generated	  by	  voltage	  clamp	  protocols	  
consisting	  of:	  Vhold	  =	  -­‐80	  mV,	  Vpre-­‐pulse	  =	  -­‐40	  mV	  for	  100ms,	  followed	  by	  Vtest	  for	  310	  
ms	  ranging	  from	  -­‐60	  mV	  to	  +80	  mV	  in	  10	  mV	  increments.	  	  The	  100	  ms	  Vpre-­‐pulse	  to	  -­‐
40	  mV	  inactivated	  voltage-­‐gated	  Na+	  currents	  (Figure	  2.2).	  For	  analysis	  of	  gating	  
currents,	  cardiomyocytes	  were	  stepped	  from	  -­‐80	  mV	  to	  a	  reversal	  potential	  
determined	  by	  the	  I/V	  curve	  for	  each	  cell	  (typically	  -­‐50	  mV)	  for	  400	  ms,	  then	  
stepped	  to	  +50	  mV	  for	  20	  ms,	  then	  back	  to	  -­‐60	  mV	  for	  tail	  current	  (Figure	  2.3).	  	  For	  
analysis	  of	  voltage	  dependence	  of	  steady	  state	  inactivation,	  myocytes	  were	  held	  at	  -­‐
80	  mV	  and	  subjected	  to	  a	  50	  ms	  pre-­‐pulse	  at	  0	  mV,	  followed	  by	  a	  2-­‐sec	  steady	  state	  
inactivation	  pulse	  from	  -­‐80	  mV	  to	  +20	  mV	  in	  10	  mV	  increments,	  then	  a	  test-­‐pulse	  to	  
0	  mV	  for	  300	  ms.	  	  	  8-­‐sec	  intervals	  elapsed	  between	  each	  recording	  sweep	  (Figure	  
2.4).	  	  Whole	  cell	  recordings	  used	  P/4	  leak	  subtraction.	  	  Activation	  voltage	  
dependence	  parameters	  were	  obtained	  by	  fitting	  current	  voltage	  curves	  to	  a	  
modified	  Boltzmann	  distribution	  of	  the	  form:	  	  :	  	  I(V)	  =	  Gmax*(V-­‐Erev)/(1+exp(V½	  -­‐	  
V)/k),	  where	  Gmax	  is	  maximal	  conductance,	  Erev	  is	  reversal	  potential,	  V½	  is	  
activation	  midpoint	  potential,	  and	  k	  is	  the	  slope	  factor.	  	  Data	  were	  analyzed	  with	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Clampfit	  9.2	  (Axon	  Instruments),	  Origin	  v7	  (OriginLab,	  Northampton,	  MA),	  and	  
unpaired	  t	  test	  with	  Welch's	  correction	  and/or	  one	  way	  Student	  t-­‐test	  statistics	  
performed	  with	  Prism	  5	  (GraphPad	  Software,	  Inc.).	  	  Sample	  sizes	  are	  listed	  in	  the	  















Figure 2.1 HEK current voltage protocol 
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Figure 2.2 Cardiomyocyte current voltage protocol 
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Figure 2.3 Cardiomyocyte gating current protocol 
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Figure 2.4 Cardiomyocyte steady-state inactivation protocol 
	   	  




Chapter 3: Regulation of CaV1.2 function by DCT and CaM 
 
3.1 Introduction 
 The	  CaV1.2	  DCT	  blocks	  LTCC	  Ba2+	  currents	  (IBa,L)	  in	  heterologous	  expression	  
systems	  [1,	  92].	   	  Early	  studies	  of	  deletion	  analysis	  of	  CaV1.2	  expressed	  in	  HEK	  cells	  
established	  the	  current	  view	  that	  DCT	  inhibits	  LTCC	  current.	  	  These	  previous	  studies	  
showed	   that	   the	   shorter	   the	   CaV1.2	   channel	   truncation,	   the	   larger	   the	   resulting	  
current	   [92].	   	   Subsequently,	   Hulme	   et	   al.	   showed	   that	   co-­‐expression	   of	   DCT	  with	  
truncated	   CaV1.2	   reduced	   IBa,L	   [1].	   	   Moreover,	   these	   studies	   indicate	   that	   DCT	   re-­‐
associates	  with	  CaV1.2	  near	   the	  CB/IQ	  domain	  on	   the	  proximal	   carboxyl	   terminus	  
(PCT).	   	   It	   is	   notable	   that	   the	   DCT	   interaction	   site	   overlaps	   the	  well	   characterized	  
CaV1.2	  PCT	  CaM	  interaction	  domains	  [93].	   	  Therefore	  it	   is	  plausible	  to	  suggest	  that	  
CaM	  may	  modulate	  DCT-­‐LTCC	  function.	  	  To	  date,	  there	  are	  no	  reports	  of	  DCT	  effects	  
on	  ICa,L	  [94].	  
3.2 Results 
 
3.2.1 DCT inhibits IBa,L, but not ICa,L  in HEKs. 
Early	   clues	   to	   the	   potential	   inhibitory	   contribution	   of	  DCT	  were	   elucidated	  
when	  studies	  used	  CaV1.2	  truncation	  at	  amino	  acid	  position	  1733	  (CaV1.2Δ1733;[30,	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76]).	   	   Subsequent	   studies	   demonstrated	   that	  DCT	  blocked	   IBa,L	  when	  DCT	  was	   co-­‐
expressed	  with	   CaV1.2Δ1801[1].	   	   I	   tested	   both	   CaV1.2Δ1733	   and	   CaV1.2Δ1801	   co-­‐
expressed	  with	   CaVβ2a	   and	   DCT	   in	   HEK	   293	   cells.	   	   CaV1.2Δ1733	   expressing	   cells	  
displayed	  DCT	  blockade	  in	  a	  similar	  pattern	  to	  that	  for	  DCT	  in	  cardiomyocytes.	  	  DCT	  
reduced	  peak	  IBa,L,	  but	  not	  ICa,L	  (Figure	  3.1).	  	  DCT	  inhibition	  of	  IBa,L	  was	  reversed	  by	  
co-­‐expression	  of	  CaM	  with	  DCT	  (Figure	  3.2).	   	  ICa,L	  and	  IBa,L	  was	  recorded	  in	  all	  cells,	  
and	   the	   relative	   difference	   between	   ICa,L	  and	   IBa,L	   serves	   as	   an	   internal	   check	   that	  
DCT	  selectively	  interferes	  with	  IBa,L	  but	  spares	  ICa,L.	   	  Note	  that	  maximal	  IBa,L	  relative	  
to	  ICa,L	  is	  distinct	  with	  DCT	  expression	  compared	  to	  other	  conditions	  (Figure	  3.1	  and	  
3.2),	  CaV1.2Δ1801	  expressing	  cells	  also	  exhibited	  DCT	  inhibition	  of	  peak	  IBa,L	  (Figure	  
3.5	   and	  3.6);	   however,	   this	  was	   accompanied	   by	   a	   corresponding	   decrease	   of	   ICa,L	  
(Figure	   3.5).	   	   Thus,	   in	   heterologous	   expression,	   both	   CaV1.2	   truncation	   constructs	  
mimic	  DCT	   attenuation	   of	   cardiomyocyte	   peak	   IBa,L.	   	   The	   absence	   of	   ICa,L	   effect	   on	  
peak	  current	  is	  also	  captured	  by	  the	  CaV1.2Δ1733	  construct.	  	  	  
DCT	  did	  not	  significantly	  alter	  the	  voltage	  dependence	  of	  activation	  for	  ICa,L	  or	  
IBa,L	   (Table	   3.1),	  with	   one	   notable	   exception.	   	   CaV1.2Δ1733	   ICa,L	   required	   a	   second	  
Boltzmann	   distribution	   to	   fit	   data	   negative	   to	   -­‐20mV	   (Figure	   3.12).	   	   There	   is	   no	  
voltage	   threshold	   for	   LTCC	   opening.	   	   Rather,	   at	   relatively	   negative	   voltages,	   open	  
probability	  (Po)	  is	  at	  very	  low	  levels.	   	  These	  results	  are	  consistent	  with	  the	  notion	  
that	  DCT	  preferentially	  inhibits	  LTCC	  when	  Po	  is	  relatively	  low.	  	  We	  could	  not	  verify	  
these	  measurements	  in	  cardiomyocytes	  because	  current	  amplitudes	  were	  too	  small.	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3.2.2 DCT has no effect on LTCC current kinetics 
 Voltage-dependent inactivation (VDI) of IBa,L is enhanced by DCT in 
cardiomyocytes (Figure 3.3 and 3.4). VDI, measured as the remaining IBa,L of 
CaV1.2Δ1801 or CaV1.2 Δ1733 channels, co-expressed with DCT, showed 
indistinguishable (Figure 3.7 and 3.8). CaM co-expression had no effect.  ICa,L decay 
kinetics was not affected by DCT (Figure 3.3 and 3.4).  The consensus finding from these 
heterologous expression studies is that IBa,L is blocked by DCT, and this block can be 
antagonized by CaM co-expression. At limiting Po, DCT blocks better.  This raises the 
notion that elevated Ca2+-entry, perhaps in complex with CaM, modulates DCT blockade.    
 
3.2.3 Role of Ca2+-CaM in CaM-DCT current restoration.   
 To	   distinguish	   between	   Ca2+	   and	   Ca2+-­‐CaM	   requirement	   for	   relief	   of	   DCT	  
blockade	   I	   co-­‐expressed	   CaM1234	   (Ca2+	   binding	   deficient	   mutant	   CaM)	   with	  
CaVΔ1733	  and	  measured	  IBa,L	  and	  ICa,L.	  	  We	  focused	  on	  CaVΔ1733	  for	  this	  experiment	  
because	  this	  construct	  captured	  DCT	  effects	  on	  cardiomyocyte	  IBa,L	  and	  ICa,L	  .	  	  Figure	  
3.9	   shows	   the	   results	   of	   CaM1234	   with	   or	   without	   DCT.	   	   CaM1234	   did	   not	   restore	  
current	   in	   cells	   co-­‐expressing	   DCT.	   Rather,	   the	   currents	   in	   both	   control	   and	   test	  
group	  were	   identical.	   	   CaM1234	   reduced	   the	   control	   IBa,L	   and	  DCT+CaM1234	   did	   not	  
result	   in	   an	   additive	   block.	   	   Comparison	   of	   IBa,L	   and	   	   ICa,L	   I(V)	   curves	   for	   CaM1234	  
expression	   (Figure	   3.9)	   to	   IBa,L	   and	   ICa,L	   I(V)	   curves	   without	   CaM1234	   (Figure	   3.9)	  
illustrates	   that	   CaM1234	   preferentially	   blocked	   IBa,L	   compared	   to	   ICa,L.	   	   CaM1234	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reduced	   CDI	   and	   compared	   to	   eGFP	   control	   or	   DCT	   co-­‐expression	   (Figure	   3.10).	  	  
Taken	  together,	  these	  results	  show	  that	  CaM1234	  and	  DCT	  individually	  exert	  similar	  
action	   on	   LTCC	   current.	   	   These	   results	   are	   consistent	   with	   a	   model	   that	   limiting	  
channel	  Po,	  and	  limiting	  Ca2+	  favors	  increased	  DCT	  blockade.	  	  
 
3.2.4 Role of Ca2+ in Time to peak current.   
Time	  to	  peak	  comparing	  CaM1234	  vs.	  CaM1234+DCT	  in	  Ca2+.	  Examination	  of	  
time	  to	  peak	  to	  test	  if	  Ca2+	  through	  the	  Ca2+	  channel	  changes	  the	  rate	  of	  activation,	  
no	  change	  was	  observed	  except	  when	  CaM1234	  was	  co-­‐express,	  then	  time	  to	  peak	  
increases	  (Figure	  3.11).	  
	  
3.2.5 DCT co-expression requires a double Boltzmann equation 
DCT	  co-­‐expression	  in	  HEKs	  requires	  a	  double	  Boltzmann	  equation	  for	  a	  
successful	  fit	  in	  Ca2+	  measured	  currents.	  	  (Figure	  3.12)-­‐	  (i)	  ICa,L	  currents	  measured	  in	  
control	  cells	  are	  successfully	  curve	  fitted	  with	  a	  single	  Boltzmann	  fit.	  	  (Figure	  3.12-­‐	  
(ii))	  ICa,L	  currents	  measured	  in	  DCT	  over-­‐expressed	  	  cells	  are	  failed	  to	  curve	  fit	  with	  a	  
single	  Boltzmann	  equation	  in	  7/8	  cells.	  Yet	  could	  be	  fitted	  with	  a	  double	  Boltzmann	  





In this dissertation I report a novel mechanisms of action of DCT on ICa,L in HEK 
293 cells that was previously not reported.   My first major finding was that DCT 
inhibited HEK IBa,L, but not ICa,L. DCT blockade of IBa,L was consistent with earlier 
studies in HEK 293 cells [1, 76]; however, literature searching earlier studies did not 
consider ICa,L.  Second, my data showed that DCT blockade was antagonized by Ca2+-
CaM.   
The first major finding of the present study, DCT blocks IBa,L but not ICa,L leads to 
the question: what kind of block?  In this section, I discuss the type of block by DCT, 
open channel block or closed channel block.  In simplest terms of voltage gated channels 
opening and closing, channels are closed at negative potential and open at relatively 
positive potentials.  Set aside inactivation for the moment by VDI and CDI as extensively 
described in the introduction.  During a sequence of closed to open, there may be 
multiple open and closed channels at the same time, thus shifting from a majority of 
closed channels to a majority of open channels.  With co-expression of DCT, I 
hypothesized that at negative potentials, even more channels will be closed operating as a 
closed channel block.  Sotalol works as a reverse use dependence potassium channel drug 
block resulting in longer action potential duration[104].  This drug binds during resting 
state and action potential duration is prolonged, however as pacing frequency increases, 
prolongation of the action potential duration decreases[104].  This action is consistent 
with reverse use dependence.  Open block starts with an increased APD and as the pacing 
frequency increases, prolongation of the APD decreases, the opposite effect of closed 
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channel block [104].  4-AP blocks ferret ventricular myocyte Ito only at hyperpolarized 
potentials and do not need Ito channels to be activated for block, but advances very 
diminutive block at positive potentials [105].  Dofetilide also acts as a reverse use 
dependent block of IKr in AT-1 cells exhibiting block at low [K]o but relieved as [K]o 
increased, similar to our hypothesis that increased cytosolic Ca through the channel 
relieves ICa,L block by DCT [106].   
Closer examination of activation of ICa,L shows that at relatively low voltages 
DCT prevents detection of measurable macroscopic ICa,L (Figure 3.12).  Use-dependent 
inhibition can be generalized as blockade of a voltage-gated ion channel that is in a 
depolarization-induced open or inactivated state.  Conversely, blockade of a channel in a 
relatively low open probability state suggest a reverse use-dependence.  Reverse use-
dependence is commonly associated with the rate-dependent action of sotatol [107, 108].   
Blockade of ICa,L,  preferentially at low potentials is consistent with a reverse use-
dependence inhibitor (RUDI). 
DCT and RGK proteins share the common feature of purportedly interfering with 
ICa,L and interacting with the CaV1.2 PCT.  Excess CaM interferes with RGK blockade of 
ICa,L manifested in alterations of peak current and slowing Ca2+-dependent inactivation 
[109].  The CaM-RGK findings motivated assessment of CaM-DCT interaction with 
respect to LTCC function.  In common with RGK modulation, CaM also interfered with 
DCT blockade; however, there was no effect on CDI nor on ICa,L for that matter.  My 
results highlight the importance of multiple proteins in the native heteromultimeric 
protein complex that comprises cardiomyocyte LTCC.  With this consideration HEK 293 
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cells serve as a minimal system whereby specific protein expression can be controlled 
simultaneously; however, missing components from native complexes must be weighed 
on interpretations of results.  The correspondence of DCT blockade of IBa,L, and the 
incomplete correspondence between HEK 293 and ICa,L for CaV1.2Δ1733 but not 
CaVΔ1801 is not completely surprising nor easily interpreted.  Importantly, in all cases 
DCT effects are competed by excess Ca-CaM.  Moreover, as first reported by Fuller et 
al.[64], we report DCT blockade of IBa,L for CaV1.2Δ1801 expressed in HEK 293 cells 
(Figure 3.5).  Despite quantitative differences, the present results for DCT effects on 
amplitude and alterations of activation gating are in common with previous reports 
confirming an auto-inhibitory function of DCT that may be propagated from DCT 
through the PCT EF-hand to channel gating[110].  
The finding that CaM-LTCC PCT tethering is Ca2+ dependent [111] raises the 
idea that apparent DCT block is better conceptualized as a dynamic CaM displacement 
by DCT.  Peptides to the CaM-interacting motif of PCT have auto-agonist [112] function.  
Conversely, in the absence of CaM, or in the presence of excess CaM1234 macroscopic 
LTCC conductance is decreased[57].  In the present study CaM1234 and DCT had similar 
and non-synergistic effects on LTCC current.  I envision that for ICa,L, compared to IBa,L, 
sufficient Ca2+-entry is achieved to strengthen CaM-PCT interaction and thus prevent 
DCT from interfering with CaM-PCT function.  The exception is low voltage whereby 
sufficiently low open channel probability limits Ca2+-entry (despite an increased driving 
force).  This effect is subtle in patch-clamp recordings, but I propose to test the CICR 
which amplifies Ca2+ signaling when measurement are made with Ca2+ imaging.  
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The finding that CaM-PCT interaction is Ca2+-dependent provides a logical 
framework to explain DCT effects.  In this scheme, DCT is expected to be a more 
effective competitor for PCT than CaM at low Ca2+, and LTCC without CaM functional 
interaction has diminished ability to open.  DCT blockade is not complete, and the 
remaining current has unaltered kinetics (Figure 3.4), consistent with the idea that the 
open channels have active CaM-PCT complexes.   
The emerging concept that DCT is a RUDI has potential physiological 
significance but first must be confirmed in a native cardiomyocyte. My findings in HEK 
293 cell propose a new mechanism of regulation of LTCC function.  Yet with a 
simplified over-expression system, other missing native interacting proteins such as  
RGKs[109], AKAP15, or CaVβ2, could potentially contribute to LTCC functional 
regulation.  The significance of DCT as a RUDI needs to be extended beyond HEK 
systems and evaluated in cardiomyocyte physiology. 
In conclusion, my data expands current understanding of DCT blockade on LTCC 
function, but only under conditions when either Ca2+ levels are low and at relatively low 
potentials.  My new hypothesis is that DCT is an intrinsic reverse use-dependent inhibitor 
of LTCC function.  The second aim of this study is to test the function of DCT in 
cardiomyocytes.  A logical extension of my findings is that DCT controls Ca2+-entry at 





Table 3.1 Voltage dependence of current activation Boltzmann fit of V1/2 and k for 




eGFP DCT CaM DCT+CaM 
30 Calcium (n) 8 8‡ 5 10 
 
V1/2, mV 7.0 ± 0.7 9.8 ± 1.7 8.2 ± 3.0 8.7 ± 0.9 
 
k, mV 10± 1.1 9.7 ± 0.5 10.1 ± 0.4 9.0 ± .2 
      30 Barium (n) 10 8 5 13 
 
V1/2 -3.1 ± 1.1 -1.3 ± 1.6 -6.5 ± 1.5 -2.4 ± 1.8 
 
k 6.7 ± 0.2 7.7 ± 0.3 7.4 ± 0.6 6.8 ± 0.4 
      CaV1.2Δ1801+β2a+ 
 
eGFP DCT CaM DCT+CaM 
30 Calcium (n) 4 10 7 11 
 
V1/2 8.6 ± 0.95 3.4 ± 0.69 11.7 ± .65 11.0 ± 0.6 
 
k 8.8 ± 0.43 9.8 ± 0.28 9.2 ± 0.31 8.9 ± 0..22 
      30 Barium (n) 4  10 7 11 
 
V1/2 2.2 ± 0.43 -1.4 ± 0.44 4.6 ± 0.35 -1.5 ± 0.50 
 
k 6.7 ± 0.25 6.9 ± 0.25 7.2 ± 0.17 6.8 ± 0.3 
A double Boltzmann equation was required to satisfy all points for DCT co-expression 
in 7/8‡ cells with 30mM Ca2+ (similar behavior with Ba2+ currents was noted by 




Figure	   3.1	   DCT	   decreases	   IBa,L,	   but	   not	   ICa,L	   from	   CaV1.2Δ1733	   truncation	  
expressed	   in	   HEK	   293	   cells.	   	  A)	   Current	   voltage	   curves	   for	   ICa,L	   (black	  
squares)	   and	   IBa,L	   (blue	   circles)	   for	   control	   (i),	   DCT	   over-­‐expression	   (ii)	  	  
Note	  the	  difference	  in	  the	  relative	  IBa,L	  versus	  ICa,L	  curves	  for	  DCT	  in	  contrast	  
to	  all	  other	  conditions.	  	  (i)	   	  Peak	  ICa,L	  density	  for	  potential	  eliciting	  maximal	  
current	   (+20mV)	   shows	   no	   significant	   difference	   by	   DCT.	  	  (ii)	   Peak	   IBa,L	  
density	   for	   potential	   eliciting	   maximal	   current	   (+5	   mV)	   is	   significantly	  
reduced	   by	   DCT.	  	  	   Unpaired	   test	   with	   Welch’s	   comparison,	   *p=0.007	   &	  
**p=0.006	  for	  DCT	  versus	  control	  and	  DCT	  respectively.	  
Figure 3.1 DCT decreases IBa,L, but not ICa,L from CaV1.2Δ1733 truncation 
expressed in HEK 293 cells  
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Figure	  3.2	  CaM	  relieves	  DCT	  decreased	  IBa,L,	  but	  not	  ICa,L	  from	  CaV1.2Δ1733	  
truncation	  expressed	  in	  HEK	  293	  cells.	   	  CaM	  over-­‐expression	  (i),	  and	  DCT+	  
CaM	   dual	   over-­‐expression	   (ii).	  	  	   DCT+CaM	   completely	   restores	   current	  
amplitude.	  	  CaM	  alone	  has	  no	  significant	  effect.	  	  Unpaired	  test	  with	  Welch’s	  
comparison,	  *p=0.007	  &	  **p=0.006	  for	  CaM	  versus	  DCT+CaM,	  respectively.	  
Figure 3.2 CaM relieves DCT decreased IBa,L, but not ICa,L from CaV1.2Δ1733 
truncation expressed in HEK 293 cells  
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Figure	   3.3	   Raw	   current	   density	   trace	   kinetics	   in	   HEK	   293	   cells.	   A)	  
CaV1.2Δ1733	   current	   density	   traces	   for	   Vhold	   -­‐80mV	   stepped	   to	   0mV	   for	  
control	   (left),	   DCT	   (center),	   and	   DCT+CaM.	   	   Ca2+	   current	   density	  
represented	  by	  black	  lines	  and	  Ba2+	  current	  density	  by	  blue	  lines.	  













0	   0	  0	  	   	  	  
	  	  
53	  
Figure	   3.4	   Fractional	   remaining	   current	   for	   CaV1.2Δ1733	   truncation	  
expressed	  in	  HEK	  293	  cells.	   	  Remaining	   fractional	  current	  300ms	  after	  the	  
peak	   for	   ICa,L	   (A),	   and	   IBa,L	   (B),	   respectively.	   	   There	   are	   no	   significant	  
differences	  for	  IBa,L	  VDI	  or	  ICa,L	  CDI	  in	  the	  heterologous	  expression	  systems.	  
	  
Figure 3.4 Fractional remaining current for CaV1.2Δ1733 truncation expressed in 
HEK 293 cells   
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Figure	   3.5	   DCT	   decreases	   IBa,,L	   and	   ICa,L	   from	   CaV1.2Δ1801	   truncation	   of	  
CaV1.2	  expressed	  in	  HEK	  293	  cells.	  A)	  Current	  voltage	  relationships	  for	  ICa,L	  
(black	  squares)	  and	  IBa,,L	   (blue	  circles)	   for	  control	  (i),	  DCT	  over-­‐expression	  
(ii).	   	   Peak	   ICa,L	   density	   for	   potential	   eliciting	   maximal	   current	   (+20mV)	  
shows	  significant	  current	  reduction	  by	  DCT	  (p<0.05).	  (ii)	  Peak	  IBa,,L	  density	  
for	  potential	  eliciting	  maximal	  current	  (+10	  mV)	  is	  significantly	  reduced	  by	  
DCT.	   	   Unpaired	   t-­‐test	   with	  Welch’s	   comparison,	   *p=0.01	   &	   **p=0.007	   for	  
DCT	  versus	  control	  respectively.	  
Figure 3.5 DCT decreases IBa,,L and ICa,L from CaV1.2Δ1801 truncation of CaV1.2 
expressed in HEK 293 cells 
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Figure	   3.6	   CaM	   relieves	  DCT	  decreased	   IBa,L,	   and	   	   ICa,L	   from	  CaV1.2Δ1801	  
truncation	   expressed	   in	   HEK	   293	   cells.	   	   A)	   CaM	   over-­‐expression	   (i),	   and	  
DCT+	   CaM	   dual	   over-­‐expression	   (ii).	   B)	   Peak	   ICa,L	   density	   for	   potential	  
eliciting	  maximal	   current	   (+20mV)	   shows	   significant	   current	   reduction	   by	  
DCT	   (p<0.05).	   C)	   Peak	   IBa,L	   density	   for	   potential	   eliciting	  maximal	   current	  
(+10	  mV)	   is	   significantly	   reduced	   by	  DCT,	   and	  DCT+CaM	   restores	   current	  
amplitude.	  CaM	  alone	  has	  no	  significant	  effect.	  Unpaired	  t-­‐test	  with	  Welch’s	  
comparison,	   *p=0.01	  &	   **p=0.007	   for	  DCT	   versus	   control	   and	  DCT	   versus	  
DCT+CaM,	  respectively	  
	  Figure 3.6 CaM relieves DCT decreased IBa,L, and  ICa,L from CaV1.2Δ1801 
truncation expressed in HEK 293 cells 
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Figure	  3.7	  Raw	  current	  density	  trace	  kinetics	  in	  HEK	  293	  cells.	  A)	  CaV1.2Δ
1801	   current	   density	   traces	   for	   Vhold	   -­‐80mV	   stepped	   to	   0mV	   for	   control	  
(left),	  DCT	  (center),	  and	  DCT+CaM.	  	   ICa,L	  density	  represented	  by	  black	  lines	  
and	  IBa,L	  	  density	  by	  blue	  lines.	  
	  
Figure 3.7 Raw current trace kinetics in HEK 293 cells  
	   	  
0	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Figure	   3.8	   Fractional	   remaining	   current	   for	   CaV1.2Δ1801	   truncation	  
expressed	  in	  HEK	  293	  cells.	   	  Remaining	   fractional	  current	  300ms	  after	  the	  
peak	   for	   ICa,L	   (A),	   and	   IBa,L	   (B),	   respectively.	   	   There	   are	   no	   significant	  
differences	   for	   IBa,L	  VDI	  or	   ICa,L	  CDI	   in	   the	  heterologous	  expression	  systems	  
respectively.	  
	  
Figure 3.8 Fractional remaining current for CaV1.2Δ1801 truncation expressed in 
EK 293 cells  
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Figure	  3.9	  CaM1234	  blocks	   IBa,L,	   and	  DCT	  block	   is	  not	  additive	   in	  HEKs.	   	  A)	  
CaV1.2Δ1733	   +	   DCT	   co-­‐expression	   with	   CaM1234	   decreases	   IBa,L,	   but	   the	  
effect	   is	   not	   additive.	   Black	   squares	   represent	   the	   30mM	   calcium	   current	  
density	  measurement	  as	  a	  change	  in	  voltage.	  Blue	  circles	  represent	  the	  same	  
cell	  with	  bulk	  flow	  displacement	  of	  30mM	  Ca2+	  with	  30mM	  Ba2+.	  There	  is	  no	  
apparent	  synergistic	  effect	  of	  DCT+CaM1234.	  
 Figure 3.9 CaM1234	  blocks	  IBa,L,	  and	  DCT block is not additive in HEK cells 
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Figure	   3.10	   Fractional	   remaining	   current	  after	  300ms	  comparing	  CaM1234	  
in	   HEKs.	   	   A)	   Remaining	   current	   after	   300ms	   comparing	   CaM1234	   vs.	  
CaM1234+DCT	   bulk	   flow	   displacement	   of	   30mM	   Ca2+	   with	   30mM	   Ba2+.	  
DCT=DCT.	   	   Black	   corresponds	   to	   cells	   without	   DCT,	   Blue	   corresponds	   to	  
cells	  co-­‐expressing	  DCT	  with	  CaM1234	  
Figure 3.10 Fractional remaining current after 300ms comparing CaM1234 in HEK 
cells   
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Figure	   3.11	   Time	   to	   peak	   expressing	   CaM1234	   in	   HEKs.	   	   A)	   Time	   to	   peak	  
comparing	   CaM1234	   vs.	   CaM1234+DCT	   using	   30mM	   Ca2+.	   No	   time	   to	   peak	  
changes	  were	  observed	  except	  when	  CaM1234	  was	  co-­‐express,	   then	  time	  to	  
peak	  increases.	  
	  
Figure 3.11 Time to peak expressing CaM1234 in HEK cells 
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Figure	   3.12	   DCT	   co-­‐expression	   in	   HEKs	   requires	   a	   double	   Boltzmann	  
equation	   for	   a	   successful	   fit	   in	   Ca2+	   measured	   currents.	   	   (i)	   ICa,L	   currents	  
measured	   in	   control	   cells	   are	   successfully	   curve	   fitted	   with	   a	   single	  
Boltzmann	  fit.	   	  (ii)	  ICa,L	  currents	  measured	  in	  DCT	  over-­‐expressed	  	  cells	  are	  
failed	  to	  curve	  fit	  with	  a	  single	  Boltzmann	  equation	  in	  7/8	  cells.	  Yet	  could	  be	  
fitted	  with	   a	   double	  Boltzmann	   equation.	   	   	   Note	   changed	   aspect	   ratios	   to	  
improve	  comparison	  to	  Figure	  3.1.	  
Figure 3.12 DCT co-expression requires a double Boltzmann equation for a 
successful fit in Ca2+ measured currents   




Chapter 4: Regulation of CaV1.2 function by DCT and CaM in Cardiomyocytes 
4.1 Introduction 
	   The	  CaV1.2	  DCT	  blocks	  LTCC	  Ba2+	  currents	  (IBa,L)	  in	  reconstituted	  HEK	  
293	   systems	   [1,	   92].	   	   My	   current	   studies	   in	   HEK	   293	   cells	   suggest	   that	   DCT	  will	  
inhibit	  LTCC	  currents.	  	  My	  HEK	  293	  data	  matches	  previous	  studies	  using	  Ba2+	  as	  the	  
charge	  carrier	  that	  resulted	  in	  larger	  current	  with	  a	  CaV1.2	  channel	  truncation	  [92].	  	  
In	   addition,	   I	   show	   lack	   of	   DCT	   block	  when	   using	   Ca2+	   as	   a	   charge	   carrier	   unlike	  
Hulme	   et	   al.	   who	   only	   showed	   that	   co-­‐expression	   of	   DCT	   with	   truncated	   CaV1.2	  
reduced	  IBa,L	  [1].	   	  These	  studies	  in	  HEK	  293	  cells	  indicate	  that	  DCT	  functionally	  re-­‐
associates	  with	  CaV1.2	  near	   the	  CB/IQ	  domain	  on	   the	  proximal	   carboxyl-­‐terminus	  
(PCT).	   	   As	   stated	   earlier	   in	   chapter	   3,	   the	   DCT	   interaction	   site	   overlaps	   the	   well	  
characterized	  CaV1.2-­‐PCT-­‐CaM	  interaction	  domains	  [93].	  	  Therefore	  it	  is	  plausible	  to	  
suggest	  that	  CaM	  may	  also	  modulate	  DCT-­‐LTCC	  function	  in	  cardiomyocytes.	  	  To	  date,	  
there	  are	  no	  reports	  of	  DCT	  effects	  on	  ICa,L,	  [94]	  or	  studies	  in	  native	  cardiomyocytes.	  
 
4.2 Results 
4.2.1	  DCT	  inhibits	  IBa,L,	  but	  not	  ICa,L	  	  in	  ventricular	  cardiomyocytes.  
	  Heterologous	  expression	  studies	  predict	   that	  cardiomyocyte	  L-­‐type	  current	  
will	  be	  inhibited	  by	  DCT	  [1].	  	  To	  test	  this,	  I	  isolated	  ventricular	  cardiomyocytes	  and	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transfected	  cells	  with	  eGFP-­‐DCT.	  	  Ca2+	  currents	  (ICa,L)	  and	  IBa,L	  were	  measured	  using	  
10	  mV	   depolarizing	   steps	   from	   a	   -­‐50	  mV	   pre-­‐pulse	   to	   inactivate	   INa.	   	   ICa,L	   (closed	  
squares)	   and	   IBa,L	   (open	   circles)	  were	  measured	   in	   the	   same	   cell	   (Figure	   4.1).	   	   As	  
expected,	  DCT	  inhibited	  IBa,L;	  however,	  DCT	  did	  not	  significantly	  reduce	  ICa,L.	  	  Vertical	  
scatter	  plots	  of	  maximal	  current	   illustrate	   the	   lack	  of	  significant	  difference	   for	   ICa,L	  
between	  eGFP	  (control)	  and	  eGFP-­‐DCT	  transfected	  cells	  (Figure	  4.2	  B).	  	  By	  contrast,	  
IBa,L	   is	   significantly	   reduced	   by	   DCT	   expression	   (Figure	   4.2	   C).	   	   By	   extension,	   I	  
postulated	   that	   CaM	   co-­‐expression	   with	   DCT	   can	   then	   functionally	   compete	   with	  
DCT	   block	   of	   IBa,L.	   	   CaM	   over-­‐expression	   alone	   has	   no	   significant	   effect	   on	  
cardiomyocyte	   ICa,L	   or	   IBa,L	   (Figure	   4.2)-­‐(i);	   however,	   CaM	   exogenous-­‐expression	  
exogenously	  expressed	  CaM	  interferes	  with	   the	  DCT	   inhibition	  of	   IBa,L	  (Figure	  4.2)-­‐
(ii).	   	  As	  expected,	   ICa,L	  was	  not	  significantly	  different	   following	  DCT	  and	  CaM	  over-­‐
expression	  (Figure	  4.2	  B).	  	  	  
 
 
4.2.2 DCT has no effect on LTCC current kinetics in cardiomyocytes 
Voltage-­‐dependent	   inactivation	   (VDI)	   of	   IBa,L	   is	   enhanced	   by	   DCT	   in	  
cardiomyocytes	   (Figure	   4.3	   and	  Figure	   4.4)–(ii).	   CaM	   co-­‐expression	   had	   no	   effect.	  	  
ICa,L	   decay	   kinetics	  was	   not	   affected	   by	  DCT	   (Figure	   4.3	   and	   Figure	   4.4)–(ii).	   	   The	  
consensus	  finding	  from	  these	  heterologous	  expression	  studies	  is	  that	  IBa,L	  is	  blocked	  
by	  DCT,	   and	   this	   block	   can	   be	   antagonized	   by	   CaM	   co-­‐expression..	   At	   limiting	   Po,	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DCT	   blocks	   better.	   	   This	   raises	   the	   notion	   that	   elevated	   Ca2+-­‐entry,	   perhaps	   in	  
complex	  with	  CaM,	  abrogates	  DCT	  blockade.	  
 
4.2.3 Role of Ca2+-CaM in CaM-DCT current restoration in cardiomyocytes.   
To	   distinguish	   between	   Ca2+	   and	   Ca2+-­‐CaM	   requirement	   for	   diastolic	   Ca2+	  
transients,	   I	   co-­‐expressed	   CaM1234	   (Ca2+	   binding	   deficient	   mutant	   CaM)	   in	  
cardiomyocytes	   and	   measured	   Ca2+	   transients.	   Figure	   4.5	   shows	   the	   results	   of	  
cardiomyocytes	  with	  or	  without	  CaM1234.	  The	  Ca2+	  transients	  in	  both	  control	  (eGFP	  
expressing	  cells)	  CaM1234	  group	  were	  identical.	   	  CaM1234	  reduced	  the	  Ca2+	  transient	  
amplitude	   and	   did	   not	   result	   in	   a	   lower	   diastolic	   phase	   Ca2+	   transient.	   	   In	   HEK	  
studies	  CaM1234	  preferentially	  blocked	  IBa,L	  compared	  to	  ICa,L.	  	  Taken	  together,	  these	  
results	  show	  that	  CaM1234	  and	  DCT	  individually	  exert	  similar	  action	  on	  LTCC	  current	  
but	   not	   Ca2+	   transients	   in	   cardiomyocytes.	   	   These	   results	   are	   consistent	   with	   a	  
model	  that	  limiting	  channel	  Po,	  and	  limiting	  Ca2+	  favors	  increased	  DCT	  blockade.	  	  
    
4.2.4 Role of DCT on Voltage-dependent inactivation 
To	  determine	  the	  effect	  on	  steady-­‐state	   inactivation,	   I	  voltage-­‐clamped	  cells	  
to	  a	  range	  of	  potentials	  for	  2	  seconds	  and	  measured	  the	  available	  current	  (Figure	  4.6	  
top	   panel).	   Steady-­‐state	   inactivation	   curves	   are	   described	   by	   single	   Boltzmann	  
distributions.	  For	  ICa,L	  there	  are	  no	  significant	  differences	  between	  control	  and	  DCT-­‐
expressing	   myocytes	   (Table	   4.2).	   For	   IBa,L	   the	   midpoint	   of	   inactivation	   is	   not	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different,	  but	  the	  slope	  factor	  is	  significantly	  steeper	  in	  the	  presence	  of	  DCT	  (Table	  
4.2).	   	   To	   determine	   if	   a	   reduced	   duration	   of	   the	   steady-­‐state	   inactivation	   affected	  
DCT	   slope	   factor,	   I	  measured	   a	   range	   of	   potentials	   for	   250ms	   (Figure	   4.6	   bottom	  
panel).	  	  The	  data	  tracks	  the	  2-­‐second	  interval	  measured	  in	  the	  previous	  figure	  with	  
no	  change	  due	  to	  a	  reduced	  inactivation	  interval.	  
 
4.2.5 DCT does not change the channel number at the surface 
To	  test	  if	  the	  channel	  number	  is	  changed	  by	  DCT	  over-­‐expression,	  I	  measured	  
gating	  charge	  movement.	   	  There	  was	  no	  significant	  difference	  among	  control,	  DCT,	  
CaM,	  or	  DCT+CaM	  groups	  (Figure	  4.7).	  	  Similarly,	  gating	  charge	  normalized	  to	  ionic	  
current	  was	  unchanged	  (Figure	  4.7	  B).	  	  These	  results	  are	  consistent	  with	  the	  notion	  
that	  DCT	  has	  no	  significant	  effect	  on	  surface	  expression	  of	  CaV1.2	  	  
4.2.6 DCT-RNAi reduces LTCC current in cardiomyocytes  
To	  test	  if	  current	  increases	  with	  reduced	  endogenous	  DCT	  in	  cardiomyocytes	  
I	   co-­‐expressed	  DCT-­‐RNAi.	   	   IBa,L	  was	   drastically	   reduced	   comparing	   control	   	  versus	  
DCT-­‐RNAi.	   	   	  However,	  the	  possibility	  that	  DCT-­‐RNAi	  may	  also	  knock	  down	  the	  full-­‐	  
length	   channel	   must	   be	   considered.	   	   I	   will	   test	   this	   by	   examining	   the	   full	   length	  
knockdown	  RNAi	   using	   calcium	   transient	   studies	   since	   IBa,L	   and	   ICa,L	  would	  be	   too	  
diminished	   in	  whole	   cell	   recordings	   for	   a	   valid	   comparison.	   	   I	   examined	   voltages	  
from	  -­‐10	  mV,	  0	  mV,	  and	  10	  mV	  	  (Figure	  4.8).	   	   	  LTCC	  ICa,L	  were	  too	  small	  to	  make	  a	  
valid	  summary	  analysis	  (data	  not	  shown).	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4.2.7 DCT-RNAi reduces LTCC Ca2+ transients in cardiomyocytes  
	  To	  test	  if	  reduced	  endogenous	  DCT	  in	  cardiomyocytes	  alter	  Ca2+	  transients,	  I	  
transfected	  cardiomyocytes	  with	  DCT-­‐RNAi.	   	  When	  comparing	  control	  versus	  DCT-­‐
RNAi,	  Ca2+	   transients	   twitch	  amplitude	  are	   reduced	   for	  DCT-­‐RNAi	  over-­‐expression	  
in	  cardiomyocytes	  and	  for	  Full	  length	  CaV1.2-­‐RNAi.	  	  (Figure	  4.9	  A)	  we	  also	  tested	  the	  
diastolic	  and	  systolic	  range	  by	  electrically	  stimulated	  myocytes	  from	  0.5	  Hz	  to	  3	  Hz	  
for	   control,	  DCT	  RNAi,	  &	  CaV1.2-­‐RNAi	   (Figure	  4.10).	   	  The	   frequency-­‐Ca2+-­‐transient	  
amplitude	   relationship	   is	   not	   apparent	   in	  DCT	  RNAi	   treated	   cells.	   	   The	  DCT-­‐RNAi	  
and	  CaV1.2-­‐RNAi	  had	  reduced	  twitch	  amplitudes.	  	  These	  results	  suggest	  a	  reduction	  
in	   the	   channel	   number	   with	   DCT-­‐RNAi	   when	   the	   results	   are	   combined	   with	   the	  
electrophysiology	   data	   in	   the	   previous	   figure.	   	     Careful characterization of mRNA 
expression in DCT-RNAi and CaV1.2-RNAi treated cells showed that both treatments 
indistinguishably coordinately reduced mRNA encoding DCT and CaV1.2.  Hence, I 




4.2.8 Long-term Ca2+ channel block in cardiomyocytes  
Since	  DCT-­‐RNAi	  results	  are	  consistent	  with	  overall	  channel	  knock	  down,	  I	  chose	  an	  
alternative	  complementary	  approach	  to	  quantify	  the	  change	  in	  the	  channel	  number	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expression	  when	  cells	  are	  blocked	  pharmacologically	  for	  48	  hours.	   	  If	  DCT	  reduces	  
diastolic	  Ca2+,	  long	  term	  remodeling	  may	  occur	  as	  part	  of	  the	  signaling	  cascade	  from	  
lower	   diastolic	   Ca2+	   and	   even	   channel	   expression	   feedback	   loop.	   	   A	   testable	  
hypothesis	   is	   that	   L-­‐type	   calcium	   currents	   contribute	   to	   L-­‐type	   calcium	   protein	  
expression.	  	  I	  support	  this	  hypothesis	  with	  following	  observations	  from	  48-­‐hour	  in-­‐
vivo	   calcium	   channel	   block	   in	   adult	   mice	   cardiomyocytes,	   1.)	   increased	   L-­‐type	  
channel	  protein	  expression,	  and	  	  2.)	  increased	  phosphatase	  protein	  expression[1].	  If	  
the	  DCT	  plays	   a	   role	   on	  L-­‐type	   calcium	   channel	   currents	   as	   a	   direct	  modulator	   of	  
current	  and	  as	  a	  result,	  changes	  channel	  transcription	  factor	  in	  cardiomyocytes,	  this	  
provides	  a	  novel	  study	  of	  feedback	  to	  L-­‐type	  calcium	  channel	  currents.	  	  Decreases	  in	  
the	  number	  of	  L-­‐type	  channel	  representative	  by	  multichannel	  recordings	  null	  events	  
after	  verapamil	  treated	  mice	  were	  treated	  with	  a	  phosphatase	  inhibitor	  okadaic	  acid	  
(OA)	   and	   db-­‐cAMP	   of	   adult	   mouse	   ventricular	   myocytes	   stepped	   from	   a	   -­‐80	   mV	  
holding	  potential	  to	  plus	  10mV	  potential	  (Figure	  4.11).	  	  Representative	  history	  plots	  
of	  events	  over	  time	  represented	  as	  successive	  sweeps	  (Figure	  4.12	  A).	  	  Summary	  bar	  
graph	  of	  nPo	  comparison	  of	  vehicle	   (ascorbic	  acid,	  AA)	  vs.	  verapamil	   treated	  mice	  
treated	   with	   phosphatase	   inhibitor	   OA	   applied	   to	   myocytes	   during	   recording	  
(Figure	   4.12	   B).	   	   	   The	   null	   fraction	   of	   Verapamil	   treated	  mice	   decreases	  with	   the	  
cAMP	  stimulation	  and	  OA	  phosphatase	   inhibition	  (Figure	  4.12C).	   In	  Figure	  4.12	  A)	  
Single	   channel	   recordings	   graphed	   as	   history	  plot	   of	   nPo	  with	   the	   addition	   of	   db-­‐
cAMP	  after	  300	  sweeps	  and	  the	  OA	  after	  600	  sweeps.	  Summary	  bar	  graphs	  of	  nPo	  
averages	  with	  standard	  error	  bar	  (Figure	  4.12	  B.)	   	  Summary	  null	  fraction	  averages	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with	   standard	   error	   bars	   (Figure	   4.12	  C.)	   	   	   The	  null	   fraction	  of	  Verapamil	   treated	  
mice	  decreases	  with	  the	  cAMP	  stimulation	  and	  OA	  phosphatase	  inhibition.	  Positive	  
controls	   for	   whole	   cell	   patch	   clamp	   in	   ascorbic	   acid	   controls	   did	   not	   respond	   to	  
increase	   in	   current	   with	   OA,	   rather	   currents	   decreased	   and	   then	   increased	   with	  
8Bromo-­‐cAMP.	   	  48	  hour	  Verapamil	   treated	  myocytes	  had	  no	  change	  with	  OA,	   and	  
increased	  similar	  to	  controls	  with	  8	  Bromo-­‐cAMP.	  	  Western	  blots	  (not	  shown)	  by	  Dr.	  
Schroder	   indicate	   an	   increase	   in	   proposed	   PP2a	   activity,	   which	   is	   near	   the	  
consensus	   phosphorylation	   site	   Ser1928	   suggesting	   LTCC	   currents	   are	   initially	  
suppressed	   with	   a	   high	   basal	   dephosphrylation	   of	   the	   channel.	   	   In	   attempts	   to	  
unmask	   the	   increase	   in	   channel	   density	   due	   to	   channel	   number	   increase,	   OA	  was	  
used	  to	  block	  phosphatase	  activity.	  	  PLB-­‐Ser16	  is	  an	  index	  for	  PKA	  phosphorylation	  
and	  was	   reduced	  with	  Verapamil	   treated	  mice	   in	   phosphor	   specific	  western	   blots	  
performed	   by	   Dr.	   Schroder.	   	   I	   hypothesized	   that	   basal	   cAMP	   levels	   were	   low	   in	  
Verapamil	   treated	   mice	   and	   designed	   a	   test	   using	   PLB	   Ser16-­‐P	   as	   a	   readout	   for	  
reversal	  with	  20	  min	   treatment	   of	   8	   bromo-­‐cAMP.	   	   PLB	   Ser	   16-­‐P	  was	   restored	   to	  
ascorbic	   acid	   controls	   (blots	   performed	   by	   Dr.	   Schroder).	   	   However,	   when	  
measuring	   SCR	   or	   whole	   cell	   patch	   clamp,	   I	   was	   not	   able	   to	   see	   a	   statistically	  
significantly	   different	   increase	   in	   nPo	   or	   LTCC	   current	   with	   OA+8Bromo-­‐cAMP,	  





4.2.9 DCT increases the dynamic range of Ca2+ transients by lowering diastolic Ca2+.  
My	   results	   are	   consistent	   with	   DCT	   preferential	   inhibition	   of	   LTCC	   under	  
conditions	  of	  relatively	  low	  Ca2+.	  	  In	  other	  words,	  DCT	  blocks	  best	  when	  the	  channel	  
is	  relatively	  inactive.	  	  I	  defined	  this	  as	  a	  reverse	  use-­‐dependent	  inhibitor	  (RUDI).	  	  It	  
is	   very	   difficult	   to	   directly	   measure	   LTCC	   blockade	   at	   low	   open	   probabilities.	  	  
However,	   LTCC	   pre-­‐amplifies	   CICR	   in	   cardiomyocytes.	   	   I	   postulate	   that	   during	  
quiescence,	  or	  at	  low	  pacing	  frequencies,	  diastolic	  Ca2+	  might	  be	  sufficiently	  low	  to	  
create	  a	  detectable	  effect	  of	  DCT.	  	  To	  test	  this	  I	  measured	  cytosolic	  Ca2+	  from	  fura-­‐2	  
loaded	   cardiomyocytes.	   	   Cardiomyocytes	   transfected	   with	   DCT	   have	   significantly	  
less	  cytosolic	  Ca2+	  during	  quiescence	   (Figure	  4.13).	   	  Cells	  were	   then	   field	  paced	  at	  
frequencies	  ranging	  from	  0.5	  to	  3	  Hz	  (Figure	  4.14	  and	  4.15).	  	  In	  all	  cases	  a	  positive	  
staircase	   for	  Ca2+	   transients	  was	  observed.	   	  Normalizing	  the	  diastolic	  Ca2+	  Ratio	   in	  
paced	   cells	   to	   that	   during	   quiescence	   reveals	   that	   DCT	   significantly	   increased	   the	  
dynamic	   range	   of	   responses	   (Figure	   4.16).	   	   The	   diastolic	   Ca2+	   ratio	   difference	  
between	  0.5	  Hz	  and	  3	  Hz	  is	  significantly	  greater	  in	  DCT	  transfected	  cardiomyocytes	  
(Figure	   4.17).	   	   I	   also	   compared	   diastolic	   and	   systolic	   ratios	   converted	   to	   nM	   Ca2+	  
(Figure	   4.18).	   	   	   In	   1.8	   mM	   bath	   Ca2+	   DCT	   significantly	   reduces	   diastolic	   [Ca2+]i	  
(Figure	  4.18	  and	  Figure	  4.19).	  	  I	  superimposed	  data	  from	  Frampton,	  et	  al,	  1991	  for	  
reference	  	  (Figure	  4.19,	  light	  grey	  filled	  squares).	  Taken	  together,	  DCT	  reduction	  of	  
quiescent	  Ca2+	  levels	  and	  increased	  dynamic	  range	  of	  Ca2+	  transients	  are	  consistent	  




4.3 Discussion  
Cardiomyocytes	   contain	   DCT	   separate	   from	   the	   LTCC	   [24,	   59,	   69].	   	   In	   the	  
present	   body	   of	   work,	   I	   report	   novel	   mechanisms	   of	   action	   of	   DCT	   on	   ICa,L	   in	  
cardiomyocytes.	  	  	  The	  first	  major	  finding	  was	  that	  DCT	  inhibited	  cardiomyocyte	  IBa,L,	  
but	   not	   ICa,L.	   	   HEK	   293	   cells	   responded	   similarly	   to	   over-­‐expressed	   DCT.	   	   DCT	  
blockade	  of	   IBa,L	  and	   tracked	  earlier	  studies	  by	  others	   labs	  using	  HEK	  293	  cells	   [1,	  
76];	  however,	  as	  previously	  stated,	  earlier	  studies	  did	  not	  consider	  ICa,L.	   	  Again,	  my	  
data	   showed	   that	  DCT	  blockade	  was	   antagonized	  by	  Ca2+-­‐CaM	  as	   seen	   in	  my	  HEK	  
293	   studies.	   	   The	   second	  major	   finding	   is	   that	  my	   results	   are	   consistent	  with	   the	  
novel	  model	  that	  DCT	  blocks	  channels	  best	  at	  conditions	  of	  low	  Ca2+	  corresponding	  
to	   low	   open	   probabilities	   with	   the	   Ca2+	   imaging	   studies.	   	   In	   essence,	   the	   data	  
suggests	   that	   DCT	   is	   a	   reverse	   use-­‐dependent	   inhibitor	   (RUDI)	   of	   LTCC	   in	  
cardiomyocytes.	   	   The	   physiological	   significance	   of	   DCT	   RUDI	   is	   revealed	   by	   the	  
increase	   of	   dynamic	   range	   of	   Ca2+-­‐transients	   to	   DCT	   as	   a	   function	   of	   stimulation	  
frequency.	  
	   The	  first	  major	  finding	  of	  the	  present	  study,	  DCT	  blocks	  IBa,L	  but	  not	  ICa,L	  leads	  
to	   the	   problem:	   how	   can	   IBa,L	   selective	   block	   be	   physiologically	   relevant?	   	   Closer	  
examination	   of	   activation	   of	   ICa,L	   in	   the	   HEK	   studies	   shows	   that	   at	   relatively	   low	  
voltages	  DCT	  prevents	  detection	  of	  measurable	  macroscopic	  ICa,L	  (Figure	  3.12).	  	  Use-­‐
dependent	  inhibition	  can	  be	  generalized	  as	  blockade	  of	  a	  voltage-­‐gated	  ion	  channel	  
that	   is	   in	   a	   depolarization-­‐induced	   open	   or	   inactivated	   state.	   	   Conversely,	   reverse	  
use-­‐dependence	   (RUDI)	   posits	   blockade	   of	   a	   channel	   in	   a	   relatively	   low	   open	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probability	   state.	   	   Blockade	   of	   ICa,L,	   	   preferentially	   at	   low	   potentials,	   and	   low-­‐
frequency	  dependent	  attenuation	  of	  Ca2+-­‐transients	  are	  consistent	  with	  RUDI.	  
My	   third	   major	   finding	   was	   excess	   exogenous	   CaM	   interferes	   with	   DCT	  
blockade	   of	   IBa,L	   without	   	   alterations	   of	   slowing	   Ca2+-­‐dependent	   inactivation	   and	  
peak	  current	   in	   cardiomyocytes	   [109].	   	  The	  CaM-­‐DCT	   findings	   in	  HEK	  293	  system	  
motivated	   assessment	   of	   CaM-­‐DCT	   interaction	   with	   respect	   to	   LTCC	   function	   in	  
cardiomyocytes.	   In	   cardiomyocytes,	   CaM	   also	   interfered	   with	   DCT	   blockade;	  
however,	   there	  was	   no	   effect	   on	   CDI	   nor	   on	   ICa,L	   as	   in	  HEK	   293	   data.	   	  My	   results	  
highlight	  the	  importance	  of	  multiple	  proteins	  in	  the	  native	  heteromultimeric	  protein	  
complex	   that	   comprises	   cardiomyocyte	  LTCC.	  DCT	  effects	   are	   competed	  by	  excess	  
Ca2+-­‐CaM.	  	  
As	  a	  logical	  extension	  to	  the	  long-­‐term	  Rem	  block,	  l	  tested	  verapamil,	  a	  
calcium	  channel	  blocker	  in	  adult	  mouse	  cardiomyocytes.	  	  Since	  we	  observed	  an	  
increase	  in	  CaV1.2	  protein	  with	  Rem	  over-­‐expression	  in	  cardiomyocytes,	  I	  predicted	  
that	  DCT	  block	  would	  have	  a	  similar	  effect	  as	  Verapamil	  calcium	  channel	  block	  for	  
48hrs.	  	  Although	  LTCC	  protein	  increased	  and	  whole	  cells	  currents	  increased	  [24],	  I	  
was	  not	  able	  to	  quantify	  SCR	  of	  increased	  nPo	  in	  the	  Ver	  treated	  adult	  myocytes.	  	  
DCT-­‐RNAi	  was	  used	  conversely	  to	  test	  if	  the	  relief	  of	  block	  would	  increase	  LTCC	  
currents.	  Unfortunately,	  whole	  cell	  LTCC	  decreased	  in	  combination	  with	  the	  
decreased	  Ca2+	  transient	  amplitude	  data.	  The	  DCT-­‐RNAi	  treated	  cardiomyocytes	  
results	  in	  very	  small	  currents.	  	  Both	  ICa,L	  and	  IBa,L	  currents	  were	  reduced.	  	  INa	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currents	  were	  voltage	  inactivated	  but	  still	  contaminated	  the	  Ca2+/Ba2+	  currents	  up	  
to	  200	  pA.	  	  To	  resolve	  this,	  I	  applied	  30uM	  TTX	  to	  the	  PSS	  for	  the	  Ca2+	  current	  
recordings.	  	  The	  resulting	  currents	  were	  either	  zero	  or	  no	  currents	  at	  all.	  	  The	  peak	  
currents	  were	  negative	  shifted	  from	  20mV	  to	  -­‐10mV	  with	  Ca2+	  and	  similar	  with	  Ba2+.	  	  
Although,	  with	  the	  other	  data	  of	  intact	  cells	  using	  Ca2+	  imaging,	  we	  note	  a	  increase	  in	  
Diastolic	  levels	  with	  RNAi	  compared	  to	  control,	  fitting	  with	  the	  RUDI	  hypothesis	  and	  
RNA/protein	  analysis	  correlate	  with	  a	  diminished	  DCT	  in	  RNAi-­‐DCT	  treated	  cells.	  	  
Our	  lab	  measured	  a	  decrease	  in	  CaV1.2	  RNA,	  but	  protein	  was	  not	  quantitated.	  
Second,	  RNAi-­‐DCT	  reduces	  both	  current	  and	  Ca2+	  twitch	  amplitude	  similar	  to	  RNAi-­‐
CaV1.2.	  	  This	  may	  suggest	  that	  RNAi-­‐DCT	  is	  also	  knocking	  down	  full	  length	  CaV1.2	  on	  
the	  background	  of	  reduced	  CaV1.2,	  evaluating	  the	  effects	  of	  DCT	  with	  such	  a	  low	  
measurable	  current	  makes	  the	  data	  unreliable	  separating	  it	  from	  contaminating	  
currents	  and	  data	  noise.	  
The	  new	  data	  with	  cardiomyocytes	  support	  the	  finding	  that	  CaM-­‐LTCC	  PCT	  
tethering	  is	  Ca2+	  dependent	  [111]	  supports	  the	  indication	  that	  seeming	  DCT	  block	  is	  
hypothesized	  as	  a	  functional	  CaM	  displacement	  by	  DCT.	  	  	  The	  cardiomyocyte	  data	  
suggests	  that	  for	  ICa,L,	  ample	  Ca2+-­‐entry	  is	  achieved	  to	  increase	  CaM-­‐PCT	  interaction	  
and	  DCT	  may	  no	  longer	  interfere	  with	  CaM-­‐PCT	  function.	  	  However,	  at	  low	  voltage	  
where	  low	  open	  channel	  probability	  limits	  Ca2+-­‐entry.	  	  This	  effect	  was	  observed	  in	  	  
patch-­‐clamp	  recordings	  in	  HEK	  studies	  but	  currents	  were	  too	  small	  to	  make	  the	  
measure	  in	  cardiomyocytes.	  	  I	  then	  chose	  to	  utilize	  the	  mechanism	  of	  CICR,	  which	  
amplifies	  Ca2+	  signaling.	  	  Reverse-­‐use	  dependence	  manifested	  as	  low	  frequency	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dependent	  DCT	  attenuation	  of	  Ca2+	  transients	  illustrates	  potential	  physiological	  
relevance	  DCT	  modulation	  of	  LTCC	  activity.	  	  
The	  supporting	  data	  in	  cardiomyocytes	  that	  CaM-­‐PCT	  interaction	  is	  Ca2+-­‐
dependent	  provides	  a	  logical	  framework	  to	  explain	  DCT	  effects.	  	  As	  suggested	  with	  
the	  HEK	  293	  data,	  DCT	  is	  likely	  to	  be	  a	  more	  effective	  competitor	  for	  PCT	  than	  
endogenous	  CaM	  at	  low	  Ca2+,	  and	  LTCC	  without	  functionally	  interacting	  CaM	  will	  
have	  lessened	  ability	  to	  open.	  	  As	  with	  the	  HEK	  293	  data,	  DCT	  inhibition	  is	  not	  
complete,	  and	  the	  remaining	  current	  has	  unaltered	  kinetics,	  coherent	  with	  the	  
notion	  that	  the	  open	  channels	  have	  active	  CaM-­‐PCT	  complexes.	  	  	  
A	  developing	  mouse	  model	  system	  was	  adopted	  for	  the	  contribution	  of	  DCT	  
to	  cardiomyocyte	  physiology.	  	  Specifically,	  my	  study	  addresses	  the	  effect	  of	  DCT	  on	  
ICa,L	  in	  a	  	  native	  cell	  environment.	  	  Developing	  cardiomyocytes	  have	  an	  advantage	  
over	  adult	  myocytes	  in	  addressing	  this	  specific	  aim.	  	  First,	  developing	  myocytes	  
have	  relatively	  large	  ICa,L[113].	  	  Second,	  developing	  cardiomyocytes	  can	  be	  
transfected	  for	  exogenous	  protein	  expression	  such	  as	  DCT	  and	  CaM	  demonstrated	  in	  
this	  paper.	  	  Finally,	  developing	  cardiomyocytes	  can	  be	  cultured	  for	  several	  days	  in	  
contrast	  to	  adult	  cardiomyocytes,	  which	  adult	  cardiomyocytes	  in	  vitro	  undergo	  a	  de-­‐
differentiation	  process	  resulting	  in	  a	  reduced	  I	  and	  do	  not	  culture	  well.	  	  Although	  
mouse	  developing	  myocytes	  are	  not	  a	  substitute	  for	  human	  adult	  myocytes,	  they	  fit	  
the	  criteria	  for	  asking	  questions	  about	  ICa,L	  current	  regulation	  by	  DCT.	  	  The	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advantages	  of	  using	  a	  developing	  cardiomyocyte	  (CM)	  as	  a	  model	  system	  is	  outlined	  
below.	  	  	  
Developing	  CMs	  have	  a	  relatively	  slow	  heart	  rate	  (HR),	  compared	  to	  mature	  
cells.	  	  Consequently	  the	  diastolic	  interval	  is	  relatively	  prolonged[114,	  
115].	  	  	  Developing	  CMs	  have	  a	  comparatively	  long	  action	  potential	  duration	  
(APD)[113,	  116].	  	  Developing	  CMs	  are	  a	  pliable	  model	  system.	  	  Developing	  CMs	  in	  
vitro	  can	  be	  pharmacologically	  treated,	  or	  genetically	  modified[102].	  	  	  	  Secondary	  to	  
the	  reduced	  HR	  and	  prolonged	  APD,	  excitation-­‐contraction	  coupling	  is	  more	  reliant	  
on	  external	  Ca2+	  compared	  to	  adult	  rodents	  [5,	  33,	  117].	  	  Thus,	  developing	  CMs	  use	  a	  
mixture	  of	  external	  and	  SR	  Ca2+	  for	  ECC	  approximately	  large	  mammalian	  systems.	  	  
The	  use	  of	  mouse	  cells	  in	  cultures	  allows	  proof	  of	  principle	  for	  future	  genetically	  
modified	  animal	  studies.	  	  	  The	  use	  of	  native	  developing	  cells	  approximates	  immature	  
phenotype	  of	  embryonic	  stem	  cell,	  and	  induced	  pluripotent	  stem	  cell	  derived	  
cardiomyocytes[118].	  	  In	  Summary,	  a	  mouse	  is	  not	  a	  large	  mammal,	  nor	  a	  human.	  	  A	  
developing	  cardiomyocyte	  is	  not	  an	  adult	  cell;	  however,	  it	  must	  be	  recognized	  that	  
in	  a	  developing	  myocytes	  emphasis	  on	  LTCC	  Ca2+	  flux	  is	  greater	  than	  SR	  Ca2+	  flux	  vs	  
adult	  myocytes.	  	  In	  rodents,	  90%	  of	  Ca2+	  handling	  is	  SR,	  where	  as	  adult	  human	  and	  
larger	  mammals	  it	  is	  50%[116].	  	  Our	  study	  seeks	  to	  understand	  the	  role	  of	  DCT	  on	  
L-­‐type	  Ca2+	  currents,	  thus	  a	  model	  system	  where	  predominant	  Ca2+	  flux	  is	  trough	  the	  
LTCC	  is	  desired	  as	  found	  in	  the	  developing	  CM	  mouse	  model[117].	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DCT	  as	  a	  RUDI	  has	  potential	  physiological	  significance.	  	  The	  purpose	  of	  this	  
study	  is	  to	  test	  the	  function	  of	  DCT	  in	  cardiomyocytes.	  As	  a	  result	  of	  my	  findings,	  I	  
propose	  a	  new	  mechanism	  of	  regulation	  of	  LTCC	  function.	  	  Determining	  the	  degree	  
of	  inherent	  RUDI	  that	  can	  be	  attributed	  to	  DCT	  in	  a	  cardiomyocyte	  will	  require	  
further	  careful	  study	  requiring	  simultaneous	  control	  of	  stoichiometries	  of	  CaM,	  
LTCC	  and	  DCT.	  	  Also,	  consideration	  of	  other	  PCT	  interacting	  proteins,	  such	  as	  
RGKs[109],	  AKAP15,	  or	  CaVβ2,	  could	  potentially	  contribute	  to	  LTCC	  functional	  
regulation.	  	  The	  significance	  of	  DCT	  as	  a	  RUDI	  extends	  beyond	  cardiomyocyte	  
physiology.	  	  From	  a	  therapeutic	  perspective,	  over-­‐expression	  of	  DCT	  is	  posited	  to	  
have	  the	  beneficial	  impact	  of	  decreasing	  Ca2+-­‐entry	  during	  diastole,	  yet	  sparing	  Ca2+-­‐
entry	  during	  systole.	  	  A	  key	  future	  stumbling	  block	  for	  application	  of	  DCT	  as	  a	  
therapeutic	  is	  of	  course	  the	  requirement	  for	  cytosolic	  delivery.	  
In	  conclusion,	  my	  data	  identify	  DCT	  blockade	  of	  LTCC	  function,	  but	  only	  
under	  conditions	  when	  either	  Ca2+	  levels	  are	  low	  and	  at	  relatively	  low	  potentials.	  	  I	  
show	  that	  DCT	  increases	  the	  stimulation	  frequency-­‐dependent	  dynamic	  range	  of	  
Ca2+	  transients	  in	  cardiomyocytes	  leading	  us	  to	  the	  new	  hypothesis	  that	  DCT	  is	  an	  
intrinsic	  reverse	  use-­‐dependent	  inhibitor	  of	  LTCC	  function.	  	  A	  logical	  extension	  of	  
my	  findings	  is	  that	  DCT	  may	  provide	  a	  novel	  therapeutic	  benefit	  by	  controlling	  Ca2+-­‐








Table 4.1 Steady state inactivation of cardiomyocyte IBa,L. 









2.5mM Barium (n) 8 7 
 
V1/2 -31 ± 1.1 -28 ± 1.1 
 
k 7.3 ± 0.52 6.1 ± 0.25* 
 
offset 0.035 ± 0.01 0.1 ± 0.021** 
 






















Figure	   4.1	   DCT	   decreases	   IBa,L,	   but	   not	   ICa,L	   in	   ventricular	  
cardiomyocytes.	  	  A)	  Current	  voltage	  curves	  for	  ICa,L	  (black	  squares)	  and	  IBa,L	  
(blue	  circles)	  for	  control	  (i),	  DCT	  over-­‐expression	  (ii).	  	  Note	  the	  difference	  in	  
the	   relative	   IBa,L	   versus	   ICa,L	   curves	   for	   DCT	   in	   contrast	   to	   all	   other	  

























Figure	   4.2	   DCT	   decreases	   IBa,L,	   but	   not	   ICa,L	   in	   ventricular	  
cardiomyocytes.	  	  A)	   Current	   voltage	   relationships	   for	   ICa,L	   (black	   squares)	  
and	  IBa,L	  (blue	  circles)	  for	  CaM	  over-­‐expression	  (i),	  and	  DCT+	  CaM	  dual	  over-­‐
expression	  (ii).	  	  B)	  Peak	  ICa,L	  density	  for	  potential	  eliciting	  maximal	  current	  
(+10mV)	   shows	  no	   significant	   difference	  by	  DCT.	  	  C)	  	  Peak	   IBa,L	   density	   for	  
potential	  eliciting	  maximal	  current	  (0	  mV)	   is	  significantly	  reduced	  by	  DCT,	  
and	   DCT+CaM	   restores	   current	   amplitude.	  	  Unpaired	   test	   with	   Welch’s	  







Figure	   4.3	   DCT	   enhances	   voltage-­‐dependent	   inactivation	   in	  
cardiomyocytes.	   	  Current	  traces	  for	  Vhold	  -­‐50mV	  stepped	  to	  0mV	  for	  control	  
(Left),	  DCT	   (center),	   and	  DCT+CaM	   (right)	   in	   cardiomyocytes.	   	   Black	   lines	  
for	  ICa,L	  and	  Blue	  for	  IBa,L.	  
Figure 4.2 DCT decreases IBa,L, but not ICa,L in ventricular cardiomyocytes  
	  












Figure	   4.4	   DCT	   enhances	   voltage-­‐dependent	   inactivation	   (VDI)	   in	  
cardiomyocytes.	  A)	  Remaining	   fractional	  current	  25ms	  and	  50ms	  after	   the	  
peak	  for	  ICa,L	  (i),	  and	  IBa,L	  (ii),	  respectively.	  DCT	  over-­‐expressing	  cells	  showed	  
a	   significantly	   greater	   VDI	   than	   control	   or	   DCT+CaM.	   Unpaired	   test	   with	  
Welch’s	   comparison,	   *p=0.04	   for	   control	   versus	   DCT,	   and	   **p=0.01	   for	  
CaM+DCT	  versus	  DCT.	  
	  
2 
Figure 4.4 DCT enhances voltage-dependent inactivation (VDI) in cardiomyocytes. 
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Figure	   4.5	   Ca2+	   and	   Ca2+-­‐CaM	   requirement	   for	   diastolic	   blockade	   in	   co-­‐
expressed	  CaM1234	  cardiomyocytes.	  With	  and	  without	  CaM1234	  co-­‐expressed	  
in	   cardiomyocytes	   and	   measured	   Ca2+	   transients.	   Left	   panel	   shows	   the	  
results	   of	   cardiomyocyte	   diastolic	   resting	   ratio	   with	   or	   without	   CaM1234.	  
CaM1234	   did	   not	   change	   diastolic	   phase	   Ca2+	   transients.	   Rather,	   the	   Ca2+	  
transients	   in	   both	   control	   and	   CaM1234	   group	   were	   identical.	   	   CaM1234	  
reduced	  the	  Ca2+	  transient	  twitch	  amplitude	  and	  CaM1234	  did	  not	  result	  in	  a	  
lower	  diastolic	  phase	  Ca2+	  transient.	  	  
Figure 4.5 Ca2+ and Ca2+-CaM requirement for diastolic blockade in co-expressed 
























































Figure	   4.6	   Voltage-­‐dependent	   inactivation	   of	   cardiomyocytes	   plus	   CaV1.2	   distal	   carboxyl	  
terminus	   1821–2171.	   A	   20	   ms	   pre	   pulse	   to	   0	   mV	   was	   followed	   sequentially	   by	   a	   series	   of	   2	  
second	  (top	  panel)	  or	  250	  ms	  (bottom	  panel)	  or	  conditioning	  pulses	  to	   the	   indicated	  potentials	  
and	  then	  by	  a	  50	  ms	  post-­‐test	  pulse	  to	  0	  mV.	  Normalized	  data	  points	  were	  obtained	  by	  dividing	  
the	  post	   test-­‐pulse	   currents	  by	   the	  peak	  values	  of	   the	  test-­‐pulse	   currents.	  Smooth	  black	   curves	  
through	   the	   data	   points	   were	   generated	   from	   a	   single	   Boltzmann	   function	   as	   described	   in	  
Methods.	  Midpoint	  of	  activation	  was	  shifted	  positive	  for	  cardiomyocytes	  +	  DCT	  in	  Ba2+.	  	  Steepness	  
of	   the	   slope	   increases	   with	   over-­‐expression	   of	   DCT	   compared	   to	   control.	   	   Boltzmann	   fit	  
parameters	  and	  sample	  sizes	  in	  Table	  4.2.	  	  
Figure 4.6 Voltage-dependent inactivation of cardiomyocytes plus CaV1.2-DCT gure 
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Figure	   4.7	   Channel	   number	   is	   unaltered	   by	   DCT	   over-­‐expression	   in	  
cardiomyocytes.	   	   A.)	   Upper	   current	   traces	   show	   representative	   gating	  
current	   measured	   by	   a	   voltage	   step	   to	   Erev	   for	   control	   (left)	   and	  
cardiomyocytes	   expressing	   DCT	   (right).	   B)	   Lower	   panels:	   (left),	   gating	  
charge	   density	   is	   not	   significantly	   different	   among	   control,	   DCT,	   CaM,	  and	  
DCT+CaM	  recordings.	  B)	  Lower	  panels	  (right),	  Ratio	  of	  gating	  charge	  to	  tail	  
current	  is	  not	  different	  among	  control,	  DCT,	  CaM,	  and	  DCT+CaM	  recordings.	  
n	  =	  4,	  3,	  4,	  and	  3	  for	  control,	  DCT,	  CaM,	  and	  DCT+CaM,	  respectively.	  	  
. 6 Voltage-dependent inactivation of Ca2+-channel current in cardiomyytes.    








Figure	  4.8	  DCT-­‐RNAi	  over-­‐expression	  in	  cardiomyocytes.	  Control	  IBa,L	  	  (i)	  vs	  
DCT	  –RNAi	  (ii)	  expressed	  in	  cardiomyocytes.	  	  Our	  lab	  measured	  a	  decrease	  
in	  CaV1.2	  RNA,	  but	  protein	  was	  not	  quantitated.	  	  	  DCT-­‐RNAi	  cells	  had	  greatly	  
reduced	  IBa,L	  	  	  versus	  control,	  n=3	  and	  n=2	  respectively.	  	  	  	  










	   	  
Control	  IBa,L	   DCT-­‐RNAi	  IBa,L	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Figure	  4.9	  Ca2+transients	  for	  DCT-­‐RNAi	  over-­‐expression	  in	  cardiomyocytes.	  	  
A)	  Electrically	  stimulated	  myocytes	  from	  0.5	  to	  3Hz	  for	  control,	  DCT	  RNAi,	  &	  
CaV1.2	  RNAi.	   	  Negative	  frequency-­‐amplitude	  relationship	  is	  not	  apparent	  in	  
DCT	  RNAi	  treated	  cells.	  	  Scale	  bars,	  0.25	  Ratio	  &	  20s.	  	  	  














Figure	   4.10	   Ca2+	   transients	   for	   DCT-­‐RNAi	   over-­‐expression	   in	   E18	  mouse	  
cardiomyocytes.	   	   DCT	   (grey)	   or	   CaV1.2	   RNAi	   (white)	   reduces	   twitch	  
amplitude.	   	  DCT	  reduces	   frequency	  dependence.	  All	  data	  show	  cells	  driven	  
by	  field	  stimulation.	  Pooled	  data	  for	  0.5	  Hz,	  1	  Hz,	  and	  2	  Hz.	  	  N=10,	  10,	  5,	  11,	  
12,	  6,	  9,	  9,	  and	  8	  respectively	  on	  the	  x-­‐axis.	  	  Control	  0.5	  Hz	  versus	  DCT-­‐RNAi,	  






































































Figure 4.10 Ca2+ transients for DCT-RNAi over-expression in E18 mouse 

















Figure	   4.11	   L-­‐type	   Calcium	   single	   channel	   events	   increase	   with	  
phosphatase	   	   inhibition.	   	  Representative	   single	   channel	   recordings	   from	   a	  
the	  same	  cardiomyocytes	  before	  drug	  (left),	   then	  elevating	  cAMP	  with	  300	  
microM	  db-­‐cAMP	  (middle),	  and	  finally	  adding	  1	  microM	  okadaic	  acid	  (right)	  
a	   phosphatase	   inhibitor,	   in	   48-­‐hour	   verapamil	   pre-­‐treated	   mice.	   Voltage	  
protocol;	  250	  ms	  depolarization	   from	  -­‐80mV	   to	  +10mV	  using	  100	  microM	  
barium	   as	   the	   charge	   carrier.	   Inward	   raw	   currents	   plotted	   as	   positive	  
inflections.	  Scale	  bars;	  indicate	  10ms	  and	  2pA	  (unitary	  currents).	  	  
	  
Figure 4.11  L-type Calcium single channel events increase with phosphatase 2Ac 
inhibition 
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Figure	  4.12	  The	  null	  fraction	  of	  48	  hour	  Verapamil	  treated	  mice	  decreases	  
with	  the	  db-­‐cAMP	  stimulation	  and	  Okadaic	  Acid	  phosphatase	  inhibition.	  	  A.)	  
Single	  channel	  recordings	  graphed	  as	  history	  plot	  of	  nPo	  with	  the	  addition	  
of	  db-­‐cAMP	  after	  300	  sweeps	  and	   the	  OA	  after	  600	  sweeps.	   	  B.)	   Summary	  
bar	   graphs	   of	   nPo	   averages	   with	   standard	   error	   bars.	   	   C.)	   Summary	   null	  
fraction	  averages	  with	  standard	  error	  bars.	  
Figure 4.12  The null fraction of 48 hour Verapamil treated mice decreases with the 
db-cAMP stimulation and Okadaic Acid phosphatase inhibition   
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Figure	   4.13	   DCT	   reduces	   quiescent	   cytosolic	   Ca2+	   and	   increases	   the	  
dynamic	   frequency	   response	   range.	   A)	   Quiescent	   cytosolic	   Ca2+-­‐level	   is	  
reduced	  by	  DCT	  expression	  (p=0.03;	  n=9	  control,	  n=14	  DCT).	  	  
Figure 4.13 DCT reduces quiescent cytosolic Ca2+ and increases the dynamic 
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Figure	  4.14	  Representative	  Ca2+	   transients	   for	  3	  Hz	  and	  0.5	  Hz	   stimulation.	  	  
Control	  (left	  panel)	  vs	  DCT	  (right	  panel)	  in	  cardiomyocytes.	   	  C)	  Pooled	  mean	  
diastolic	  Ca2+	  level	  normalized	  to	  quiescent	  value	  for	  0.5,	  1,	  2,	  and	  3	  Hz.	  Note	  
the	  increase	  in	  dynamic	  response	  range	  for	  DCT-­‐transfected	  cardiomyocytes.	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Figure	  4.15	  Representative	  Ca2+	  transients	  for	  3	  Hz	  and	  0.5	  Hz	  stimulation	  
for	   DCT+CaM	   versus	   CaM	   in	   cardiomyocytes.	   	   DCT+CaM	   also	   reduces	  
quiescent	   cytosolic	   Ca2+	   and	   increases	   the	   dynamic	   frequency	   response	  
range.	   	   Quiescent	   cytosolic	   fura-­‐2	   fluorescent	   ratio	   (Rq)	   is	   reduced	   by	  
DCT+CaM	   expression.	   	   The	   horizontal	   dashed	   line	   is	   the	   Rq	   from	   Figure	  
4.13.	  	  Pooled	  mean	  diastolic	  fura-­‐2	  ratio	  (Rdiastolic)	  normalized	  to	  Rq	  for	  0.5,	  
















Figure	  4.16	  Pooled	  mean	  diastolic	  Ca2+	  level	  normalized	  to	  quiescent	  value	  
for	   0.5,	   1,	   2,	   and	   3	   Hz.	   Rdiastolic	   values	   from	   Figures	   4.14	   &	   4.15	   were	  
divided	  by	  Rq	  values	  in	  Figure	  4.13.	  	  Note	  the	  increase	  in	  dynamic	  response	  
range	  for	  DCT-­‐transfected	  cardiomyocytes.	  
	  
Figure 4.16 Pooled mean diastolic Ca2+ level normalized to quiescent value for 0.5, 1, 
















Figure	  4.17	  Response	  range	  manifested	  as	  difference	  between	  3	  Hz	  and	  0.5	  
Hz.	   DCT	   significantly	   increased	   response	   range	   *(p=0.0100)	   compared	   to	  
eGFP	  controls.	  
	  


















Figure	   4.18	   DCT	   decreases	   diastolic	   calcium	   in	   cardiomyocytes.	   	  	  A)	  
Calcium	   transients	   induced	   by	   0.5	   Hz	  electrical	   field	   stimulation	   from	  
1.8mM	   bath	   Ca2+,	   and	   6mM	   Ca2+.	   	  Horizontal	   dashed	   lines	   shown	   for	  














Figure	   4.19	   DCT	   decreases	   diastolic	   calcium	   in	   cardiomyocytes	   and	  
increases	   systolic	   calcium	   transients.	   	  	   Calcium	   transients	   induced	   by	   0.5	  
Hz	  electrical	   field	   stimulation	   from	  1.8mM	  bath	  Ca2+,	   and	   6mM	  Ca2+.	   	  	   The	  
relationship	   between	   diastolic	   and	   systolic	   calcium	   transients	   in	  
cardiomyocytes	   over-­‐expressing	   DCT	   (closed	   circles,	   dashed	   line)	   vs.	  
control	  (open	  squares,	  solid	  line)	  at	  1.8	  and	  6mM	  calcium	  respectively.	  	  The	  
light	   gray	   solid	   squares	   shows	   data	   from	   Frampton,	   Orchard,	   and	   Boyett	  
(1991)	  for	  2	  and	  6mM	  Ca2+	  for	  reference.	   	  *p=0.04	  for	  diastolic	  DCT	  versus	  
control	  (n=12	  and	  n=6,	  respectively).	  
Figure 4.19 DCT decreases diastolic calcium in cardiomyocytes and increases 
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Figure	   4.20	   Model	   of	   DCT	   inhibition.	   	   CaM	   over-­‐expression	   completely	  
reverses	   DCT	   function	   inhibition	   at	   Low	   Ca2+	   (using	   Ba2+	   as	   the	   charge	  
carrier	   in	   whole	   cell	   electrophysiology)	   concentrations	   (top	   left	   to	   right).	  	  
Electrically	  pacing	  cardiomyocytes	  elevates	  cytosolic	  Ca2+	  and	  relieves	  DCT	  
functional	   block	   in	   diastolic	   phase	   of	   the	   transients	   (top	   left	   to	   bottom	  





Chapter 5.  Dissertation Summary 
	   The	  data	  presented	  in	  this	  dissertation	  provides	  supporting	  evidence	  of	  the	  
global	  hypothesis	  that	  low	  cytosolic	  calcium	  enhances	  DCT	  auto-­‐inhibition	  of	  CaV1.2	  
L-­‐type	  calcium	  currents	  in	  cardiomyocytes.	  	  When	  channel	  Po	  is	  low	  at	  low	  voltages,	  
DCT	  acts	  to	  lower	  Po	  further,	  thus	  reducing	  the	  amount	  of	  calcium	  through	  the	  
calcium	  channel.	  	  
5.1 Major Findings 
5.1.1 DCT blocks Ba2+ current, not Ca2+ current in HEKs 
Chapter	   3	   describes	   the	   first	   novel	   finding	   of	   this	   dissertation	  project.	   	   Co-­‐
expression	   of	   a	   truncated	   CaV1.2	   channel	   with	   DCT	   lowers	   channel	   Po	   at	   low	  
voltages.	   	   The	   result	   of	   studies	   showed	   that	   DCT	   inhibited	  HEK	   IBa,L,	   but	   not	   ICa,L.	  	  
DCT	  blockade	  of	   IBa,L	  was	   consistent	  with	   earlier	   studies	   in	  HEK	  293	   cells	   [1,	   76];	  
however,	  I	  was	  the	  first	  to	  consider	  ICa,L.	  	  Second,	  my	  data	  showed	  that	  DCT	  blockade	  
was	  antagonized	  by	  Ca2+-­‐CaM.	  	  Our	  labs	  previous	  findings	  demonstrated	  CaM	  could	  
interfere	  with	  another	  protein	  associated	  with	  the	  CaV1.2-­‐PCT.	  	  RGK,	  a	  small	  GTPase,	  
can	   strongly	   inhibit	   CaV1.2	   current	   and	   associates	   with	   the	   CaV1.2-­‐PCT.	   The	   RGK	  
studies	   showed	   CaM	   over-­‐expression	   in	   HEK	   cells	   with	   CaV1.2	   plus	   Rem	   could	  
rescue	   Rem	   current	   block.	   	   Since	   the	   CaV1.2-­‐PCT	   near	   the	   CB/IQ	   is	   the	   site	   of	  
dynamic	   protein	   interactions,	   it	  was	   proposed	   that	   CaM	  might	   also	   interfere	  with	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Cav1.2-­‐PCT—DCT	   functional	   interaction.	   	   However,	   in	   chapter	   4	   I	   did	   not	   see	  
reversal	   of	   CaM-­‐DCT	   diastolic	   ratio	   in	   cardiomyocyte	   Fura-­‐2	   experiments.	   	   An	  
alternative	   explanation	   to	   the	   HEK	   and	   cardiomyocyte	   whole	   cell	   current	   data	  
maybe	  that	  CaM	  increases	  Po	  by	  binding	  CB/IQ	  domains,	  and	  reversing	  DCT	  block.	  	  
Po	   increases	   with	   increased	   CaM-­‐binding	   IQ	   domain	   mimetic	   peptide	   (IQmp)	   in	  
LTCC	  [112].	  	  Low	  [Ca2+]i	  is	  a	  requirement	  for	  the	  observed	  increase	  in	  LTCC	  Po	  [112].	  	  	  
Another	  proximal-­‐carboxyl	  terminus	  CaM-­‐binding	  domain	  mimetic	  peptide	  (CBmp)	  
added	  to	  isolated	  rabbit	  ventricular	  myocytes	  increased	  single	  channel	  Po	  on	  LTCC	  
in	   a	   CaMKII	   and	   Ca2+/CaM	   independent	   manner	   [112].	   	   My	   result	   with	   CaM	  
reversing	  IBa,L	  fits	  the	  criteria	  of	  1.)	  excess	  CaM	  is	  available	  to	  bind	  IQ	  or	  CB	  domain,	  
and	  2.)	   low	  cytosolic	  Ca2+	  through	  pipette	  buffers	  EGTA	  and	  using	  a	  Ca2+	   free	  bath	  
solution	  with	  Ba	  as	  the	  main	  charge	  carrier	  conducting	  through	  LTCC.	  
I	   postulate	   that	   DCT	   block	   of	   LTCC	   current	   is	   a	   closed	   state	   block.	   	   I	   will	  
describe	   some	   open	   and	   closed	   state	   blockers	   with	   examples	   of	   reverse	   use	  
dependence.	  A	  simple	  model	  of	  channel	  opening	  and	  closing	   is	  a	  channel	  closed	  at	  
negative	   potential	   and	   open	   at	   positive	   potentials.	   	   I	   hypothesized	   that	   DCT	   will	  
block	   a	   greater	   number	   of	   channels	   at	   negative	   potentials,	   resulting	   in	   more	  
channels	   remaining	   closed	   and	   DCT	   operating	   as	   a	   closed	   channel	   block.	   	   Sotalol	  
works	  as	  a	  reverse	  use	  dependence	  potassium	  channel	  drug	  block,	  thus	  resulting	  in	  
longer	   action	   potential	   duration.	   	   Sotalol	   binds	   during	   resting	   state	   and	   action	  
potential	   duration	   is	   prolonged,	   however	   as	   pacing	   frequency	   increases,	  
prolongation	   of	   the	   action	   potential	   duration	   decreases[104].	   	   This	   action	   is	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consistent	  with	  reverse	  use	  dependence.	   	  Open	  block	  starts	  with	  an	  increased	  APD	  
and	   as	   the	   pacing	   frequency	   increases,	   prolongation	   of	   the	   APD	   decreases,	   the	  
opposite	   effect	   of	   closed	   channel	   block	   [104].	   	   4-­‐AP	   blocks	   ferret	   ventricular	  
myocyte	   Ito	   only	   at	   hyperpolarized	  potentials	   and	  do	  not	  need	   Ito	   channels	   to	   be	  
activated	  for	  block,	  but	  advances	  very	  diminutive	  block	  at	  positive	  potentials	  [105].	  	  
Dofetilide	  also	  acts	  as	  a	  reverse	  use	  dependent	  block	  of	  IKr	  in	  AT-­‐1	  cells	  exhibiting	  
block	   at	   low	   [K+]o	   but	   relieved	   as	   [K+]o	   increased,	   similar	   to	   our	   hypothesis	   that	  
increased	  cytosolic	  Ca2+	  through	  the	  channel	  relieves	  ICa,L	  block	  by	  DCT	  [106].	  	  	  
	  
5.1.2 DCT blocks Ba2+ current, not Ca2+ current in cardiomyocytes. 
	   Chapter	  4	  describes	  the	  novel	  findings	  of	  DCT	  regulation	  of	  L-­‐type	  calcium	  
channel	  currents	  in	  cardiomyocytes.	  	  This	  is	  the	  first	  time	  DCT	  has	  been	  evaluated	  
on	  a	  background	  of	  native	  CaV1.2.	  	  As	  predicted	  by	  my	  heterologous	  studies,	  DCT	  
over-­‐expression	  blocks	  IBa,L,	  but	  not	  ICa,L	  in	  whole	  cell	  electrophysiology	  experiments	  
using	  cardiomyocytes.	  	  Since	  my	  hypothesis	  predicts	  that	  DCT	  lowers	  an	  already	  low	  
Po,	  detection	  of	  the	  DCT	  inhibition	  in	  electrophysiology	  experiments	  was	  below	  
measurable	  detection.	  	  I	  therefore	  used	  intact	  cardiomyocytes	  over-­‐expressing	  DCT	  
in	  electrically	  field-­‐stimulated	  cells	  using	  calcium	  imaging.	  	  By	  controlling	  the	  pacing	  
stimulation	  rate	  from	  quiescent	  cells	  to	  0.5	  Hz	  up	  to	  3	  Hz,	  I	  was	  able	  to	  increase	  
cytosolic	  calcium	  concentrations.	  	  The	  novel	  finding	  shows	  that	  DCT	  lowers	  diastolic	  
calcium	  at	  rest	  and	  increases	  the	  dynamic	  range	  for	  twitch	  amplitude	  as	  frequency	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of	  electrical	  pacing	  is	  increased.	  	  A	  follow-­‐up	  experiment	  to	  directly	  test	  the	  effect	  of	  
DCT	  on	  Po	  would	  test	  cardiomyocytes	  in	  the	  cell-­‐attached	  configuration.	  	  	  I	  would	  
measure	  the	  single	  channel	  openings	  and	  predict	  that	  DCT	  co-­‐expression	  would	  
increase	  the	  null	  fraction	  versus	  controls.	  	  However,	  the	  charge	  carrier	  would	  be	  
limited	  to	  Ba2+	  because	  single	  channel	  currents	  in	  Ca2+	  	  are	  indistinguishable	  from	  
noise.	  My	  next	  major	  finding	  was	  excess	  exogenous	  CaM	  interferes	  with	  DCT	  
blockade	  of	  IBa,L.	  However,	  there	  was	  no	  effect	  on	  CDI	  nor	  on	  ICa,L	  as	  in	  HEK	  293	  data.	  	  
My	  results	  highlight	  the	  importance	  of	  multiple	  proteins	  in	  the	  native	  
heteromultimeric	  protein	  complex	  that	  comprises	  cardiomyocyte	  LTCC.	  	  DCT	  effects	  
are	  competed	  by	  excess	  Ca2+-­‐CaM.	  	  
The	  combined	  results	  from	  Chapter	  3	  and	  Chapter	  4	  supports	  a	  hypothesis	  
that	  DCT	  auto-­‐inhibition	  is	  relieved	  when	  cytosolic	  calcium	  increases.	  	  I	  define	  this	  
as	  a	  reverse	  use	  dependent	  inhibitor,	  or	  RUDI.	  	  The	  significance	  of	  DCT	  as	  a	  RUDI	  
contributes	  a	  new	  approach	  in	  understanding	  cardiomyocyte	  physiology	  and	  
reconstituted	  HEK	  293	  systems.	  	  Based	  in	  these	  studies,	  over-­‐expression	  of	  DCT	  is	  
postulated	  to	  decrease	  Ca2+-­‐entry	  during	  diastole,	  yet	  spare	  Ca2+-­‐entry	  during	  
systole.	  	  Lowering	  diastolic	  calcium	  is	  a	  key	  beneficial	  therapeutic	  approach,	  but	  
current	  cytosolic	  delivery	  systems	  limit	  the	  application	  of	  DCT	  as	  a	  therapeutic.	  
In	  conclusion,	  first	  my	  data	  refines	  the	  role	  of	  DCT	  blockade	  of	  LTCC	  function,	  
but	  only	  under	  conditions	  when	  either	  Ca2+	  levels	  are	  low	  and	  at	  relatively	  low	  
potentials.	  	  Second,	  I	  show	  that	  DCT	  increases	  the	  stimulation	  frequency-­‐dependent	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dynamic	  range	  of	  Ca2+	  transients	  in	  cardiomyocytes	  leading	  us	  to	  the	  new	  
hypothesis	  that	  DCT	  is	  an	  intrinsic	  reverse	  use-­‐dependent	  inhibitor	  of	  LTCC	  function.	  	  
In	  summary,	  DCT	  may	  provide	  a	  novel	  therapeutic	  benefit	  by	  controlling	  Ca2+-­‐entry	  
at	  diastolic	  potentials	  while	  sparing	  Ca2+-­‐entry	  for	  systole.	  
	  
5.2 Future Directions 
5.2.1 DCT Ser1928 modifies Ca2+ transient response to Isoproteranol 
To	   establish	   if	  modulation	   of	   DCT	   inhibition	   is	   regulated	   by	   the	   consensus	  
phosphorylation	   site	   on	   the	   DCT,	   I	   tested	   DCT	  with	   a	   phospho-­‐deficient	   target	   at	  
Ser1928.	   	  This	  is	  a	  logical	  extension	  to	  test	  if	  auto-­‐inhibition	  of	  LTCC	  by	  DCT	  over-­‐
expression	   in	   cardiomyocytes	   could	   be	   overcome	   by	   increasing	   the	   Po	   of	   the	  
channel	  by	  β-­‐adrenergic	  expression.	  Cardiomyocytes	  were	  loaded	  with	  Fura-­‐2	  AM,	  
2uM	  for	  8	  minutes	  then	  paced	  at	  1Hz	  for	  1	  minute,	  then	  exposed	  to	  2uM	  iso,	  paced	  
for	  2	  min	  (Figure	  5.1).	  	  Means	  represent	  average	  steady	  state	  of	  more	  than	  40	  points,	  
or	   transients.	   	   Serine	   (S	   or	   Ser)	   to	   Glutamate	   (Glu	   or	   E)	   mimics	   phosphorylated	  
Ser1928	  and	  Ser	  to	  Ala	  mimics	  phosphor-­‐deficient	  Ser1928.	   	  The	  twitch	  amplitude	  
actually	   increased	  with	   the	  phospho-­‐deficient	   Ser1928	   and	   resembled	  DCT	   twitch	  
amplitudes	  with	  Ser1928Glu.	   	  One	   interpretation	   is	   that	  phosphorylated	  DCT	  does	  
not	  reduce	  the	  diastolic	  Ca2+	  phase	  of	  the	  transient,	  while	  the	  dephosphorylated	  DCT	  
is	   associated	   with	   the	   channel	   and	   can	   increase	   the	   dynamic	   range	   by	   lowering	  
diastolic	  Ca2+	  phase	  transient	  levels.	   	  This	  would	  be	  consistent	  with	  low	  Ca2+	  entry	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through	   the	  LTCC	  retaining	  DCT	  auto-­‐inhibition.	   	  Yet	  once	  phosphorylated,	  DCT	   is	  
not	   longer	   associated	   with	   the	   channel	   and	   does	   not	   lower	   diastolic	   Ca2+,	   but	  
amplitude	   is	   increased	   by	   more	   Ca2+	   coming	   through	   the	   channel	   and	   β-­‐AR	  
response	  with	  enhanced	  CDI.	  
Next	   I	   consider	   the	   other	   possibility	   of	   β-­‐AR	   regulation	   that	   both	   my	  
preliminary	  data	   from	   future	   studies	   support	   as	  well	   as	   recent	   reports	   by	   Fu	   and	  
Ganesan[65]	   [119].	   	   First	   I	   must	   determine	   the	   role	   of	   DCT	   on	   β-­‐AR	   response	   in	  
adult	  myocytes.	  	  I	  propose	  to	  develop	  a	  mouse	  with	  knock	  in	  fluorescent	  GFP	  of	  the	  
Cav1.2-­‐DCT.	   	   This	   will	   allow	   delineation	   between	   DCT	   and	   non-­‐DCT	   associated	  
Cav1.2	  channels.	  	  Then	  I	  can	  monitor	  the	  activity	  of	  each	  channel	  in	  the	  presence	  of	  
β-­‐AR	  stimulation	  to	  see	  if	  DCT	  indeed	  plays	  a	  role	  in	  the	  signal	  transduction	  of	  the	  β-­‐
AR	   stimulation.	   	   Ca2+	   sparks	   provide	   the	   ideal	   readout	   for	   this	   experiment	  with	   a	  
localized	   Ca2+	   event	   tied	   to	   a	   given	   local	   channel	   complex’s	   response.	   	   Highly	  
localized	   spatial	   and	   temporal	   increases	   in	   Ca2+	   during	   the	   low	   activity	   of	   Ca2+	  
channels	  are	  called	  sparks[120].	  	  I	  predict	  that	  in	  the	  absence	  of	  β-­‐AR	  response,	  that	  
DCT	   will	   lower	   the	   Po	   and	   in	   turn	   reduce	   the	   spark	   number	   and	   frequency	  
measured.	   	   Second,	   if	   I	   measure	   a	   CaV1.2	   without	   DCT	   associated,	   I	   predict	   an	  
increase	  in	  spark	  number	  and	  frequency.	  	  Third,	  I	  predict	  that	  the	  phosphorylation	  
by	  β-­‐AR	  stimulation	  in	  the	  presence	  of	  DCT	  will	  be	  equal	  or	  greater	  than	  the	  spark	  
frequency	  of	  β-­‐AR	  stimulated	  channel	  in	  the	  absence	  of	  DCT	  associated	  with	  CaV1.2	  
channel.	  	  If	  the	  last	  result	  is	  negative,	  I	  must	  consider	  the	  stoichiometry	  of	  DCT	  and	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AKAP15	  that	  plays	  a	  role	  in	  PKA	  localization	  to	  the	  channel[64].	  	  Furthermore,	  I	  can	  
introduce	   trypsin	   or	   carboxylpeptidase	   A	   to	   enhance	   currents	   from	   a	   predicted	  
increase	   in	   proteolytic	   processing	   of	   CaV1.2	   in	   vivo	   [119].	   	   To	   address	   the	  
shortcomings	  of	  the	  Fu	  paper,	  I	  must	  design	  a	  test	  to	  address	  if	  DCT	  is	  required	  for	  
cell	  surface	   localization	  of	  the	  CaV1.2	  channel	   in	  cardiomyocytes.	   	  They	  considered	  
the	  possibility	  that	  DCT	  may	  result	   in	  a	  dysregulation	  of	  CaV1.2	  gene	  expression.	   	  I	  
could	  assess	  the	  cardiac	  function	  for	  HR,	  EF%,	  FS%	  as	  in	  Houser’s	  paper	  [121]	  
Finally,	  another	  interesting	  aspect	  of	  the	  Cav1.2-­‐DCT	  is	  the	  undefined	  role	  of	  
Ser1928,	   a	   PKA	   phosphorylation	   site	   (ref	   first	   description).	   	   Ganesan	   reported	   a	  
Ser1928A	  expression	  in	  CM	  that	  shows	  ineffective	  alteration	  in	  ISO	  response	  [65].	  	  I	  
have	   taken	   this	   one	   step	   further	   in	   the	   preliminary	   results	   in	   Ca	   imaging	   using	   a	  
Ser1928E	  to	  mimic	  phosphorylation	  status	  of	  DCT	  with	  an	  opposite	  than	  expected	  
result.	  	  	  Interestingly,	  Youn	  has	  proposed	  that	  Ser1928	  is	  required	  for	  CDI	  regulation	  
by	  AKAP15	  and	  CaN	  [122].	  	  	  
 
5.2.2 DCT over-expression is required for ISO response in cardiomyocytes. 
In	   order	   to	   understand	   the	   effects	   of	   the	   previous	   data	   using	   phospho-­‐
deficient	   DCT,	   I	   compared	   cardiomyocytes	   with	   and	   without	   DCT	   over-­‐expressed	  
with	   the	   addition	   of	   isoproterenol.	   Figure	   5.2	   shows	   Raw	   Ca2+	   transients	   using	  
cardiomyocytes	  paces	  at	  1Hz	   for	  1	  min,	   then	  expose	   to	  2uM	   ISO,	  paced	   for	  2	  min,	  
then	   0Ca2+	   +	   Caffeine	   after	   20	   seconds.	   	  Means	   represent	   average	   steady	   state	   of	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more	   than	   40	   points,	   or	   transients.	   	   It	   is	   notable	   that	   twitch	   amplitudes	   do	   not	  
change	  except	  when	  DCT	  is	  over-­‐expressed.	  	  This	  DCT	  diastolic	  baseline	  is	  reduced	  
in	  cardiomyocytes	  vs.	  control	  with	  pre-­‐post	  ISO,	  which	  is	  consistent	  with	  my	  global	  
hypothesis	   of	   DCT	   acting	   as	   a	   RUDI.	   	   The	   complementary	   direction	   proposed	   to	  
continue	  the	  evaluation	  of	  DCT	  on	  β-­‐AR	  response	   in	  cardiomyocytes	   ,	  1)	  evaluate	  
the	   current	   amplitudes	   using	   electrophysiology	   DCT	   over-­‐expression	   in	   the	  
presence	   of	   ISO,	   2)	   examine	   the	   steady-­‐state	   inactivation	   of	   DCT	   over-­‐expressed	  
cardiomyocytes	   in	   the	   presence	   of	   ISO.	   	   One	   limitation	   to	   the	   whole	   cell	  
electrophysiology	   is	   the	   increase	   in	   background	   currents	   when	   stimulating	  









Figure	  5.1	  Cardiomyocytes	  respond	  to	  ISO	  when	  co-­‐expressed	  with	  DCT.	  No	  
change	   was	   observed	   with	   the	   addition	   of	   ISO	   in	   cardiomyocytes	   in	   the	  
absence	   of	   DCT	   or	   with	   DCT-­‐S1928A	   and	   DCT-­‐S1928E	   phospho-­‐deficient	  
and	   phospho-­‐mimetic	  mutants.	   	   Cardiomyocytes	  were	   loaded	  with	   Fura-­‐2	  
am,	   2uM	   for	   8	  min	   then	   paces	   at	   1Hz	   for	   1	  min,	   then	   expose	   to	   2uM	   ISO,	  
paced	   for	   2	  min.	   	  Means	   represent	   average	   steady	   state	   of	   more	   than	   40	  
Figure 5.1 Cardiomyocytes respond to ISO when co-expressed with DCT  
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Figure	   5.2.	   	   Raw	   Ca2+-­‐transients	   using	   Cardiomyocytes	   paces	   at	   1Hz.	  	  
Cardiomyocytes	  were	   paced	   for	   1	  min,	   then	   expose	   to	   2uM	   isoproterenol	  
(ISO),	  paced	  for	  2	  min,	  followed	  by	  0Ca	  +	  Caffeine	  after	  20	  seconds.	  	  Means	  
represent	  average	  steady	  state	  of	  more	  than	  40	  points,	  or	  transients.	  	  Twitch	  
amplitudes	   do	   not	   change	   except	   when	   DCT	   is	   over-­‐expressed.	   	   DCT	  
diastolic	  baseline	  trends	   lower	   in	  cardiomyocytes	  versus	  control	  with	  pre-­‐
post	  ISO.	  	  Students	  t-­‐test	  *p=0.022.	  
  Figure 5.2.  Raw Ca2+-transients using Cardiomyocytes paces at 1Hz  
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